Endocannabinoid-controlled modulation of orexinergic neurons in obesity: switch from excitatory to inhibitory wiring by IMPERATORE ROBERTA
                                             
 
UNIVERSITA’ DEGLI STUDI DI VERONA 
 
DIPARTIMENTO DI  
SCIENZE NEUROLOGICHE, NEUROPSICOLOGICHE, 
MORFOLOGICHE E MOTORIE  
 
 
SCUOLA DI DOTTORATO DI 
SCIENZE INGEGNERIA MEDICINA 
 
 
DOTTORATO DI RICERCA IN 
NEUROSCIENZE 
 
 
Con il contributo di  
ISTITUTO DI CIBERNETICA “E.CAIANIELLO” C.N.R. POZZUOLI 
 
 
CICLO XXIV 
 
 
 “ENDOCANNABINOID-CONTROLLED MODULATION OF 
OREXINERGIC NEURONS IN OBESITY: SWITCH FROM 
EXCITATORY TO INHIBITORY WIRING” 
 
S.S.D. BIO/17 
 
 
  Coordinatore: Prof. Michele Tinazzi 
 
  
   Tutor: Dr. Luigia Cristino 
 
   
       
Dottorando: Dr. Roberta Imperatore 
 
                
 
2 
 
INDEX 
 
INTRODUCTION  ................................................................................. 5 
          Abstract  ............................................................................................... 6 
          The Endocannabinoid System  ............................................................. 8 
          The Endocannabinoid System: biochemical and molecular aspects  . 11  
          The endocannabinoid system: Therapeutic effects  ........................... 16 
            The orexinergic system ...................................................................... 18 
           Distribution of orexinergic system  ................................................... 20 
             Functions of orexinergic system  ....................................................... 22  
           Lateral hypothalamic area ................................................................. 25 
           Leptin  ................................................................................................ 28  
           Hypothalamic endocannabinoids, orexin and leptin interaction in the  
                 control of food intake .................................................................. 31 
 
AIMS  ......................................................................................................... 34 
          Aims  .................................................................................................. 35 
 
MATERIALS AND METHODS  .................................................... 37 
          Experimental procedures .................................................................... 38 
3 
 
          Perfusion and preparation of tissue sections ...................................... 38 
            Leptin injection  .................................................................................. 39  
          Immunofluorescence and peroxidase based immunohistochemistry 39 
 
          Pre-embedding immunogold-silver labeling ...................................... 41 
          Pre-embedding immunogold labeling ................................................ 42  
          Quantitative analysis of immunogold labeling ................................... 43 
   Pre-proorexin mRNA quantification by RT-PCR analysis ................ 44 
    Electrophysiology  ............................................................................. 45 
   Lipid extraction and endocannabinoid measurement ......................... 46 
   Statistical analyses  ............................................................................. 47 
 
RESULTS  ................................................................................................ 48 
          The endocannabinoid system is expressed in OX-A neurons ............ 49 
          2-AG levels are upregulated in orexinergic neurons of ob/ob mice and  
                mice with HFD-induced Obesity   ................................................ 50 
          Obesity is accompanied by increased pre-proorexin mRNA                                                                                                                 
                 expression in the LH and increased OX-A signaling in the  
                 arcuate nucleus ............................................................................ 51 
         CB1–expressing fibers innervating orexinergic neurons are rearranged  
                during obesity ............................................................................... 51 
4 
 
         Functional evidence for the stronger inhibitory innervation of ob/ob  
                orexinergic neurons ...................................................................... 53 
         Modulation of inhibitory synaptic activity onto orexinergic neurons by  
                 CB1 .............................................................................................. 54 
         The shift from excitatory to inhibitory CB1-expressing inputs onto    
                  OX-A neurons, and its stimulation of orexin release, are reversed                     
                   by leptin administration in ob/ob mice ...................................... 56 
 
DISCUSSION AND CONCLUSIONS  .......................................... 57 
          Discussion  ......................................................................................... 58 
          Conclusions  ....................................................................................... 61 
 
FIGURES  ................................................................................................ 62 
 
BIBLIOGRAPHY  ................................................................................ 82 
 
 
 
 
 
 
 
 
5 
 
INTRODUCTION 
6 
 
ABSTRACT 
 
 
Acute or chronic alterations in energy status lead to changes in the balance 
between excitatory and inhibitory synaptic transmission and associated 
synaptic plasticity, facilitating adaptation of energy metabolism to new 
homeostatic requirements. The impact of such changes, especially during 
obesity, on endocannabinoid signalling at CB1 receptors, a master 
modulator of synaptic transmission and strength, and a target for anti-
obesity drugs, is not well understood. Endocannabinoids stimulate food 
intake and their synthesis and release increase after food-deprivation thus 
inducing activation of CB1 receptors. In particular, endocannabinoid levels 
increase in the hypothalamus and blood during short-term fasting (1, 2) and 
decrease after leptin administration and feeding (3, 4). Impairment of leptin 
signaling (db/db mice expressing a defective leptin receptor), leptin 
deficiency (ob/ob), and leptin resistance (acquired resistance due to diet-
induced obesity, HFD mice) in mice showed elevated levels of 
Endocannabinoids in the hypothalamus and in adipose tissue (5). Recent 
papers show that leptin modulates also the axonal growth and synaptic 
plasticity within the hypothalamus (6,7). In particular, leptin increases 
neurite extension in the Arcuate Nucleus during mouse perinatal 
development, thus playing an early trophic role within those circuits that 
will be the target of leptin physiological actions in adult life (6). Leptin also 
may act on the Orexinergic-synthesizing (OX) neurons of the lateral 
hypothalamus, which send widespread projections to the brain (8) playing a 
strategic integrative role in the feeding. Leptin suppress the activity of OX 
neurons, the biosynthesis of OX or both. Moreover, an OX1R-selective 
antagonist reduced food intake and ameliorated obesity of leptin-deficient 
ob/ob mice (9), suggesting that leptin deficiency at least partly activates the 
orexin pathway to increase food intake. On the other hand, pretreatment 
with subeffective doses of rimonabant, a selective CB1 antagonist, 
attenuates the orexigenic actions of OX (10), whereas electrophysiological 
data support the inhibitory role of cannabinoids on orexinergic neurons in 
physiological conditions (11). Staring from these bases, we investigated if a 
remodeling of orexinergic neuronal wiring occurs in the LH during a 
prolonged nutritional perturbation caused by, or resulting in, leptin 
signalling deficiency, as in ob/ob and HFD mice, respectively, and its 
impact on neuromodulatory function of the endocannabinoid system, since 
high neural plasticity occurs in this circuitry for adequate regulation of 
energy balance (12). 
 
7 
 
Alterazioni acute o croniche dello stato energetico provocano cambiamenti 
negli equilibri tra trasmissione sinaptica eccitatoria ed inibitoria e nella 
plasticità sinaptica ad essi associata, favorendo l'adattamento del 
metabolismo energetico alle nuove esigenze omeostatiche. L'impatto di tali 
cambiamenti, in particolare durante l'obesità, sul segnale degli 
endocannabinoidi sui recettori CB1, uno dei principali modulatori della 
trasmissione sinaptica, e uno dei target per i farmaci anti-obesità, non è ben 
compreso. Gli endocannabinoidi stimolano l'assunzione di cibo e la loro 
sintesi e rilascio aumentano dopo deprivazione di cibo, inducendo così 
l'attivazione dei recettori CB1. In particolare i livelli di endocannabinoidi 
aumentano nell'ipotalamo e  nel sangue durante brevi periodi di digiuno (1, 
2) e diminuiscono in seguito a somministrazione di leptina e dopo 
assunzione di cibo (3, 4). Topi con riduzione dei segnali della leptina (topi 
db/db che esprimono un recettore difettoso della leptina), con carenza di 
leptina (ob/ob), e con resistenza alla leptina (resistenza acquisita a causa 
dell’ obesità indotta da dieta, topi HFD) presentano elevati livelli di 
endocannabinoidi nell'ipotalamo e nel tessuto adiposo (5). Lavori recenti 
mostrano che la leptina modula anche la crescita degli assoni e la plasticità 
sinaptica nell'ipotalamo (6,7). In particolare, la leptina incrementa 
l’estensione degli assoni nel Nucleo Arcuato durante lo sviluppo perinatale 
del topo, svolgendo così un ruolo trofico all'interno di quei circuiti che 
saranno oggetto delle azioni fisiologiche della leptina nella vita adulta (6). 
La leptina può anche agire sui neuroni sintetizzanti Orexina (OX) 
dell'ipotalamo laterale, i quali inviano proiezioni diffuse al cervello (8) 
svolgendo un ruolo integrativo strategico nell'alimentazione. La leptina 
sopprime l'attività dei neuroni OX, la loro biosintesi o entrambi. Inoltre, un 
antagonista selettivo del recettore OX1R riduce l’assunzione di cibo e 
diminuisce l’obesità in topi ob/ob (9), suggerendo che la carenza di leptina, 
almeno in parte, attiva il patway dell’orexina per aumentare l'assunzione di 
cibo. D'altra parte, il pretrattamento con dosi sub-efficaci di rimonabant, un 
antagonista selettivo del CB1, attenua l’azione oressigenica dell’OX (10), 
mentre dati elettrofisiologici sostengono un ruolo inibitorio dei cannabinoidi 
sui neuroni orexinergici in condizioni fisiologiche (11). Partendo da queste 
basi, abbiamo studiato se un rimodellamento del wiring neuronale 
orexinergico si verifica nell’LH nel corso di una prolungata perturbazione 
nutrizionale causata da, o risultante in, carenza di segnalazione della leptina, 
come in topi ob/ob e topi HFD, rispettivamente, ed il suo impatto sulla 
funzione neuromodulatoria del sistema endocannabinoide, dato che un’ alta 
plasticità neuronale si verifica in questo circuito per un’ adeguata 
regolazione del bilancio energetico (12). 
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The Endocannabnoid System 
 
Cannabis sativa has been used since antiquity to treat many ailments, 
including eating disorders. In 1964 a group of Israeli researchers was able to 
isolate and synthesize the delta-9-tetraidrocannabinolo (∆9-THC), the most 
powerful of the numerous active ingredients in cannabis (13, 14). Since that 
time, there have been many dramatic breakthroughs in understanding the 
molecular mechanisms underlying the pharmacological action of ∆9-THC. 
More recently, in 1988, researchers discovered the presence in the body of a 
membrane receptor capable of being activated by ∆9-THC (15). These 
discoveries have opened new horizons to a possible therapeutic use of 
Cannabis sativa. Cannabis contains over 400 chemical compounds, of which 
70  are structurally related to ∆9-THC and are collectively known as 
cannabinoids (16). Some of these compounds possess THC-like effects, 
though many act through different mechanisms of action and possess 
unknown pharmacology. The term cannabinoids usually displayed not 
only the cannabinoids from plant, but also all the ligands of cannabinoid 
receptors, i.e. those of plant origin, but also the endogenous 
molecules and some molecules of synthetic origin. These molecules are 
called, respectively, fitocannabinoids,  endocannabinoids (ECs) and 
"classic cannabinoids" (to distinguish them from synthetic molecules, with 
a not cannabinoid structure but still able to activate the cannabinoid 
receptors). The chemical characterization of the ∆9-THC by Mechoulam 
and Gaoni in 1964 had allowed a number of important clarifications, 
especially regarding its mechanism of action (13,14). The studies focused 
more on ∆9-THC because of its clear psychotropic activity and the social 
implications of it. The strong hydrophobic nature of this compound 
suggested that its effects might be due to a general non-specific perturbation 
of cell membranes rather than to a specific interaction with selective binding 
sites. It was only thanks to the synthesis of enantiomers of THC and its 
synthetic analogues (17, 18), and to the subsequent discovery that its 
principal pharmacological actions were enantioselective, that the idea of a 
‘cannabinoid’ receptor was put forward. The discovery of the cannabinoid 
receptor was a completely random event because it happened in the course 
of an accurate screening of the DNA of the rat to find the genes of receptors 
for the neurochinine. On that occasion, in fact, was found an "orphan 
ligand" receptor, whose distribution coincided with a known brain 
cannabinoid radiolabeled ligand ([3H]-CP-55940). The suspicion that it was 
the cannabinoid receptor, was finally confirmed in 1988, when subsequent 
investigations decreed that the isolated receptor in rat brain, was actually the 
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specific receptor through which cannabinoids mediate behavioral and 
pharmacological effects (15). This receptor was named CB1, because 
shortly after, was identified, by homology cloning, a second receptor, CB2, 
which explained the immunosuppressive effects of cannabis derivatives in 
the immune system. Subsequently, the two receptor subtypes were better 
characterized: the CB1 receptor has been cloned in 1990 (19) while the CB2 
receptor has been cloned in 1993 (20). The two cloned receptor subtypes 
(CB1 and CB2) belong to the family of membrane receptors coupled to G 
proteins and, as such, they present a single polypeptide chain that crosses 
the plasma membrane seven times. The amino acid sequence has the amino 
terminus, with the sites of glycosylation, on the extracellular side and the 
carboxyl terminus, with the sites of phosphorylation, on the intracellular 
side. Both receptors are Gi/o protein-coupled receptors type, being able to 
inhibit adenylyl cyclase and to activate the mitogen-activated protein kinase 
(MAPK) (21).  The activation of CB1 is also able to inhibit the L-, N-, and 
P/Q-type voltage-gated calcium channels (22, 23), while it has the opposite 
effect on A-type potassium channels and on inwardly-rectifying Kþ 
channels (24). In some cases, the activation of the CB1 stimulates 
phospholipase C, thus indicating its coupling with a protein of the type Gq 
or Gs (25). Studies carried out immediately after the molecular 
characterization of CB1 and CB2 receptors established the distribution of 
their mRNAs in several mammalian tissues, with a very high abundance of 
CB1 in the central nervous system (CNS) and in peripheral tissue (e.g., liver 
and adipocytes), and of CB2 in immunocompetent cells and tissues. We 
now know, however, that both receptors, and CB1 in particular, are much 
more widely distributed than originally believed. For example, the liver, 
initially used as a ‘negative control’ to validate probes and antibodies 
designed to detect the CB1 receptor, is now known to express a low but 
nevertheless functionally important amount of this protein (26). On the other 
hand, the CB2 receptors, the existence of which in the brain had been 
initially ruled out, have been shown to be expressed in low amounts also in 
this organ during neuroinflammatory conditions (27), and even in central 
neurons under physiological conditions (28, 29). As a consequence, the 
original idea that CB1 receptors played a role almost uniquely in the brain, 
and CB2 in the immune system, has now evolved into the concept that 
either cannabinoid receptor type might control several general central and 
peripheral functions, including neuronal development, transmission and 
inflammation, cardiovascular, respiratory and reproductive functions, 
hormone release and action, bone formation and energy metabolism, as well 
as cellular functions such as cell architecture, proliferation, motility, 
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adhesion and apoptosis (30-33). The wide distribution of CB1 throughout 
the CNS explains the plethora of physiological processes that this system 
modulates, including cognition, pain, memory, attention, reward, motor 
behavior, and feeding. Specifically, in terms of energy regulation and 
feeding behavior, CB1 receptors can be found in the hypothalamus, nucleus 
accumbens, vagus nerve, nodose ganglion, myenteric neurons, epithelial 
cells of the gastrointestinal tract, adipocytes, and the liver (34, 35). At the 
level of the peripheral nervous system, CB1 was found in peripheral sensory 
fibers and autosomal (interneurons in the spinal dorsal root ganglia, the 
myenteric neurons in the pre-junctional fibers of the bladder and in the 
superior cervical ganglion sympathetic fibers) in perfect agreement with 
some of the reported effects on nociception and functions of the vascular 
and gastrointestinal tract (34, 36-38). The CB2 receptor instead, at least in 
physiological conditions, turns out to be much more abundant in the 
immune system (mast cells, B cells, T lymphocytes) where it is implicated 
in the control of both humoral and cellular immune response (39, 40). The 
revelation of the existence of specific receptors for THC was quickly 
followed by the frantic search of endogenous ligands for these proteins 
(endocannabinoids, ECs). THC acts upon an endogenous cannabinoid 
system (ECS) that modulates a variety of physiological systems, including 
pain, inflammation, feeding, energy balance, memory, attention, and reward 
processing. This rather complex and pleiotropic endogenous signalling 
system was discovered in the late 1990s, starting from studies on the 
mechanism of action of ∆9-THC. This system includes: 1) at least two G-
protein-coupled receptors, known as the cannabinoid CB1 and CB2 
receptors;  2) the endogenous agonists at these receptors, known as 
endocannabinoids, of which anandamide (AEA) and 2-arachidonoylglycerol 
(2-AG) are the best known; and  3) proteins and enzymes for the regulation 
of endocannabinoid levels and action at receptors (Fig.1). 
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Fig. 1: Overview of the molecular composition of the Endocannabinoid 
system 
 
 
 
The endocannabinoid system: biochemical and molecular aspects 
 
The discovery of the CB1 receptor was followed, in 1992, by the isolation, 
from the pig brain, of the first endogenous metabolite able to bind 
selectively to this protein. The first such compound to be discovered was 
anandamide (AEA, arachidonoyl ethanolamide, from the Sanskrit word 
ananda for ‘bliss’) (41), and this finding was soon to be followed by the 
identification of the cannabimimetic properties of an already known 
endogenous metabolite, 2-arachidonoylglycerol (2-AG) (42, 43). The AEA 
is able to bind both receptor subtypes behaving as a partial agonist (44, 45); 
also the 2-AG is able to activate both receptor subtypes, however, behaving 
as a full agonist (42). The fact that there were endogenous molecules able to 
play a physiological role, necessarily imply the existence of biosynthetic 
pathways adjustable, or of specific molecular mechanisms able to synthesize 
these substances in the appropriate ways, places and times. Also, must 
necessarily exist a catabolic pathway can be adjusted to terminate the signal 
at the appropriate time. The ECs are considered as local neuromodulators 
that, unlike other neuromodulators, are not stored in secretory vesicles, but 
are produced on demand (on request) from the cells, from precursors of 
membrane before being released into the extracellular side, similarly to 
other eicosanoids such as prostaglandins. ECs are produced 'on demand' to 
help restore the levels and function of other mediators (including excitatory 
and inhibitory neurotransmitters) after acute or chronic alterations of the 
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physiological homeostasis of the cell (31). In the nervous system the ECs 
work as retrograde messengers from the post-synaptic to presynaptic 
terminals where they modulate (inhibit) neurotransmitter release through 
activation of CB1 receptors (46). Thus, endocannabinoids can either 
facilitate inhibitory or excitatory post-synaptic potentials depending upon 
the type of neurons on which their receptors are expressed. Moreover, they 
have been discovered to play a prominent role both in short-term and in 
long-term synaptic plasticity, as well as to directly control the rate of firing 
of presynaptic cells. The short-term inhibitory actions of cannabinoids on 
afferent GABAergic and glutamatergic transmission are respectively known 
as depolarization-induced suppression of inhibition, or DSI, and 
depolarization-induced suppression of excitation, or DSE. DSI/DSE are well 
characterized in the hippocampus and cerebellum and have been observed in 
other brain areas (47,48) (Fig.2). 
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Fig. 2: Regulation of presynaptic ion channel activities by CB1 cannabinoid 
receptors. a) At synapses between GABA ( -aminobutyric acid) 
interneurons and pyramidal cells: activation of CB1 receptors can initiate a 
series of intracellular events, which include (1) activation of G-protein –  
subunits, (2) closure of voltage-gated Ca2+ channels and (3) inhibition of 
GABA release. b) At parallel fibre–Purkinje cell synapses in the cerebellum: 
CB1 activation can (1) engage G-protein -subunits that (2) cause the 
opening of K+ channels; the resulting membrane hyperpolarization can (3) 
reduce Ca2+ entry and inhibit glutamate release. Mechanisms similar to 
those illustrated above are thought to underlie cannabinoid-mediated 
inhibition of neurotransmitter release in other brain regions. 
 
 
 
 
 
 
 
14 
 
Studies on the biosynthetic and catabolic pathways and enzymes for 
anandamide and 2-AG started immediately after their discovery. The AEA 
is biosynthesized by the hydrolysis of the corresponding N-acyl-
phosphatidylethanolamine (NAPE) through the work of a specific 
phospholipase type D Ca2+-dependent (NAPE-PLD) that shows peculiar 
properties than other known PLD, in fact it belongs to the family of zinc-
metal hydrolase of the β-lactamase (49). NAPE was shown to be produced 
from the transfer of arachidonic acid from the sn-1 position of membrane 
phospholipids to the nitrogen atom of phosphatidylethanolamine (50). 
Whereas diacylglycerol (DAG) precursors for 2-AG were shown to be 
produced either from the phospholipase-C-catalysed hydrolysis of 
phosphatidylinositol or from the hydrolysis of phosphatidic acid (51, 
52). Have recently been cloned and characterized two isozymes of DAG 
lipase (DAGLα and DAGLβ) responsible for hydrolysis of the ester bond 
selective present at position sn-1 of the DAGs (53). Once synthesized, the 
ECs are released outside the cell, where do they bind to receptors on 
neighboring cells or on the same cell that produced them, acting as 
autocrine or paracrine mediators. Their fat-soluble nature, in fact, not favors 
the spread in the extracellular matrix or in the blood. Turning off the signal 
ECs provides, therefore, the re-uptake by the cell, enzymatic hydrolysis and 
re-esterification of the products obtained in membrane phospholipids. The 
re-uptake of ECs acts through a transport mechanism of facilitated diffusion 
driven by a specific carrier of membrane that would be able to work in both 
directions (incoming and outgoing from the cell) according to the 
gradient concentration of ECs across the plasma membrane. The existence 
of a specific carrier is still debated. After being seized by extracelluar side, 
the ECs, within the cell, are subject to enzymatic hydrolysis. Both AEA and 
2-AG were found to be inactivated mostly by enzymatic hydrolysis of the 
amide and ester bonds, respectively, and the major enzymes responsible for 
these reactions were cloned and named fatty acid amide hydrolase (FAAH) 
(54), and monoacylglycerol lipase (MAGL) (55, 56), respectively. The 
FAAH is an integral membrane protein of approximately 64kDa which 
works at alkaline pH (the optimum is at pH 9.0), is formed from 597 amino 
acids and has a highly conserved sequence amidase, rich in glycine and 
serine residues. Studies of immunohistochemical and in situ hybridization, 
have confirmed that the expression of this enzyme in the various brain areas 
is directly related to the density of the CB1 receptor (57). The MAGL is 
present both on cytosol and plasma membrane  where recognize 2-
monoacylglycerols AG as a substrate (58, 59). The MAGL is a protein of 
33kDa which belongs to the family of serine hydrolases expressed 
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especially in those areas of the brain where the CB1 receptors are more 
present (Fig. 3).  
 
 
 
 
 
 
 
Fig. 3: a) Biosynthesis and degradation pathways of Endocannabinoids. b) 
The endocannabinoid system in neurons. Diet-derived 6-polyunsaturated 
fatty acids ( 6-PUFAs) are incorporated into membrane phospholipids, 
which can subsequently be metabolized into the two major 
endocannabinoids, 2-AG and anandamide, by membrane-associated 
enzymes. Degradative enzymes for endocannabinoids are localized to 
internal membranes. Leptin signaling can influence 2-AG biosynthesis in 
the hypothalamus and anandamide hydrolysis in T-lymphocytes. CB1 is 
located mostly presynaptically, allowing for retrograde action of 
endocannabinoids. DAGL: sn-1 selective diacylglycerol lipase; EMT: 
putative endocannabinoid membrane transporters; FAAH: fatty acid amide 
hydrolase; MAGL: monoacylglycerol lipase; NArPE: N-arachidonoyl-
phosphatidyl-ethanolamine; NAPE-PLD: N-acyl-phosphatidylethanolamine 
selective phospholipase D. Blunt-ended line indicates inhibition. 
 
 
 
 
 
 
 
a b 
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The endocannabinoid system: therapeutic effects 
 
Considering the robust nature of cannabinoid activity, it is no surprise then 
that it is an area of interest for a wide range of potential therapeutic 
applications: the stimulation of this system reduces chemotherapy-induced 
nausea and emesis, increases appetite, and may stimulate lipogenesis. 
Nonetheless, a considerable amount of interest remains in understanding the 
role of the ECS in energy regulation. The effects of THC are mediated 
through the endocannabinoid system (ECS), which promotes a positive 
energy balance through stimulation of appetite as well as shifting 
homeostatic mechanisms toward energy storage. One of the best known 
pharmacological actions of THC on the brain is to reduce sensitivity to pain, 
for this is very useful as analgesic against diseases such as recurrent 
headaches or menstrual pain, but above all, by offering an anti-
inflammatory is also useful in other types of pain such as those due to 
rheumatism (60-62). Cannabinoids are able to decontract the musculature, 
in fact, have an effect on muscle relaxant and antispastic. The first study on 
the effect of THC on beneficial muscle spasms of multiple sclerosis dates 
from the late ‘70 (63), recently, but was also shown the involvement of the 
ECS in the control of spasticity in some models animals of multiple 
sclerosis (64-67). The abundance of the EC and CB1 receptors in those 
regions of the basal ganglia (globus pallidus and substantia nigra), members 
of the movement, have prompted researchers to find out if the ECs were 
involved in the regulation of movement and, consequently, to take 
advantage of this involvement in related diseases. In an animal model of 
Parkinson's disease has been observed in increased levels of ECs in the 
reduction of movement in rats treated with reserpine, an animal model of 
Parkinson's disease (68); in another study was instead, demonstrated the 
possible involvement of ECs in the onset of dyskinesia, a troublesome side 
effect of levodopa therapy (69). The ECs are also involved in Alzheimer's 
disease, have been reported, in fact, the alterations in the ECS in tissues 
affected by this disease (70) and in addition, recently, it has been discovered 
that cannabinoids are able to counteract the effects of amyloid beta peptide 
(responsible for the neurodegeneration linked to Alzheimer's disease) (71, 
72). Also as part of the neuro-degenerative diseases, studies have been 
conducted on Huntington's disease and has been observed a reduction of 
CB1 receptors in the globus pallidus and in the caudate-putamen in an 
animal model generated by the injection of 3-nitropropionic acid (73). The 
same group of researchers has realized, as a result, a work that demonstrates 
the therapeutic efficacy of THC in an animal model of Huntington 
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generated by injection of malonate (74). Other studies have been conducted 
in psychotic patients with schizophrenia, where it was observed that THC 
aggravates the symptoms of schizophrenia (75) suggesting that the basis of 
this disorder may be caused by malfunction of the ECS. The association of 
the latter with the circuits in the brain dopamine has been extensively 
investigated both from an anatomical point of view, that the biochemical 
and pharmacological (76) and confirmation of this, it was recently reported 
a study in which shows an alteration of the EC system in schizophrenic 
patients, not only in the central nervous system, but also in the blood (77). 
Cannabinoids also stimulate the appetite by acting through the activation of 
CB1 receptors, this observation suggested, therefore, the use of CB1 
antagonists in the treatment of obesity. It is expected, in fact, the next 
marketing a selective antagonist of CB1 (Rimonabant, Acomplia) with the 
statement. In a study conducted on 48 mice genetically modified (deficient 
for the CB1), it was shown that the EC involved in fat metabolism by acting 
at the level of hepatic lipogenesis (26). The EC are also involved in some 
eating disorders because their blood levels are increased in anorexia nervosa 
(3). It was finally shown that malnutrition in pregnancy are decreased 
hypothalamic levels of AEA in the newborn, confirming that the ECs also 
play a crucial role in neonatal development (78). 
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The orexinergic system 
 
In 1998, de Lecea et al. (79) discovered two mRNAs encoding for the same 
neuropeptides, named hypocretin-1 and -2. In the same year, Sakurai et al. 
(8) independently discovered the same neuropeptides while screening for 
ligands for orphan G-protein-coupled receptors, named orexin A and B 
(OX-A and OX-B). OX-A and OX-B constitute a novel distinct peptide 
family, showing no significant homology with any previously described 
peptides (80). These peptides have been called orexin, from the Greek 
word "orexis" meaning appetite, since the mRNA for the precursor 
of these peptides is expressed abundantly and specifically in the perifornical 
area of the LH, a region normally involved in the central regulation of 
feeding behavior and energy homeostasis (8, 80). Molecular cloning studies 
showed that both OX-A and OX-B are derived from a common precursor 
polypeptide of 131 amino-acid, prepro-orexin, with usual proteolytic 
processing presumably by pro-hormone convertases.   OX-A is a 33-amino 
acid peptide of 3562 Da with two sets of intrachain disulfide bonds. It has 
an N-terminal pyroglutamyl residue and C-terminal amidation (8). The 
primary structure of OX-A predicted from the cDNA sequences is 
completely conserved among several mammalian species (human, rat, 
mouse, cow, sheep, dog, and pig). On the other hand, rat OX-B is a 28-
amino acid, C-terminally amidated linear peptide of 2937 Da that is 46% 
(13/28) identical in sequence to OX-A. The C-terminal half of OX-B is very 
similar to that of OX-A (73%; 11/15), whereas the N-terminal half is 
variable. OX-B also has a high degree of sequence similarity among species. 
In the same year, by means of experiments, Sakurai et al. have also 
identified two subtypes of orexinergic receptors: orexin receptor-1 
and orexin receptor-2 (OX1R and OX2R) (Fig.4).  OX1R  was initially 
identified as an expressed sequence tag from human brain (8, 81). 
Subsequently, OX2R was identified by searching an expressed sequence tag 
database by tBLASTn with the OX1R sequence as a query (8). The amino 
acid identity between the fullength human OX1R and OX2R sequences is 
64%. Amino acid identities between the human and rat counterparts of each 
of these receptors are 94% for OX1R and 95% for OX2R, indicating that 
both receptor genes are highly conserved between the species (8).  
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Fig. 4: An overview of the orexin system. a) Orexins and their receptors. 
OX-A and OX-B are derived from a common precursor peptide, prepro-
orexin. The actions of orexins are mediated via two G protein–coupled 
receptors OX1R and OX2R. OX1R is selective for orexin A, whereas OX2R is 
a nonselective receptor for both OX-A and OX-B. OX1R is coupled 
exclusively to the Gq subclass of heterotrimeric G proteins, whereas OX2R 
couples to Gi/o and /or Gq. It was revealed that the orexin receptors have 
different binding profiles for the respective orexinergic peptides: OX1R has 
greater affinity for OX-A than OX-B by 1 order of magnitude; in contrast, 
OX2R has similar affinity for both OX-A and OX-B (8). Furthermore, OX1R 
is coupled to the Gq/11 class of G proteins, which results in activation of 
phospholipase C with subsequent triggering of the phosphatidylinositol 
cascade and influx of extracellular Na+ and Ca2+, presumably through TRP 
channels to cause depolarization of neurons. OX2R is shown to be coupled 
to both Gq/11 and inhibitory Gi proteins when expressed in cell lines (82). 
So while OX-A and OX-B themselves are very similar, they may mediate 
distinct actions via binding to their receptors. b) Structure of mature OX-A 
and OX-B peptides. The topology of the two-intrachain bonds in OX-A is 
indicated above the sequence. Shadows indicate amino acid identity. 
Mammalian OX-A sequences thus far identified (human, rat, mouse, pig, 
dog, sheep, and cow) are all identical, whereas the sequences of OX-B show 
some differences among species.  
 
 
 
 
 
 
 
 
a b 
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Distribution of orexinergic system 
 
One of the most distinctive features of the orexinergic system is its 
restricted localization to a few thousand neurons in the lateral 
hypothalamus. The highest density of OX-immunoreactive fibres is 
observed within the hypothalamus, including the lateral hypothalamic area 
(LHA), perifornical area and posterior hypothalamus (83-85), with 
innervations in the lateral, dorsal and posterior areas, the paraventricular 
hypothalamic nucleus (PVN), arcurate nucleus (ARC) and supramammillary 
nucleus (83-85). Outside the hypothalamus, high OX terminal density can 
be observed in the following brain nuclei: locus coeruleus, septum, bed 
nucleus of the stria terminalis, thalamic paraventricular and reunion nuclei, 
periaqueductual grey, substantia nigra, raphe peribrachial pontine region, 
medullary reticular formation and the nucleus of the solitary tract. Less 
prominent projections are detectable in the cortex, amygdala, hippocampus 
and olfactory bulb (83, 85, 86). One of the primary reciprocal projection 
bundles innervates nuclei of the ascending arousal system such as the 
cholinergic pedunculopontine and laterodorsal tegmental nuclei, the 
serotonergic dorsal and median raphe nuclei, the noradrenergic LC, and the 
histaminergic tuberomammillary nucleus (83). By using conventional (87) 
and transgene-based (88) retrograde tracing several groups have shown that 
hypothalamic nuclei involved in circadian and metabolic integration such as 
the ARC nucleus, dorsomedial hypothalamus (DMH) and PVN nuclei send 
projections to OX cells. This anatomical structure suggests that the activity 
of OX neurons influences multiple brain areas. OX neurons were also 
showed to receive innervations from regions associated with energy 
homeostasis including neuropeptide Y- (NPY), agouti-related peptide, and 
α-melaninstimulating hormone-immunoreactive fibers, which presumably 
come from the ARC (89, 90). Despite colocalization of OX-A and OX-B in 
cell bodies (85), fibres immunoreactive for OX-A are more common in the 
brain than those immunoreactive for OX-B (91, 92). In the central nervous 
system, in situ hybridization studies have demonstrated that both OX 
receptor mRNAs are expressed in regions in which contain dense orexin 
innervations. OX1R and OX2R mRNAs show partially overlapping but 
largely distinct and complementary distribution patterns, suggesting that 
they play different physiological roles for each receptor subtype. OX1R is 
expressed in many brain regions, such as the prefrontal and infralimbic 
cortex, hippocampus (cornu ammonis 2), amygdala, and bed nucleus of the 
stria terminalis (BST), paraventricular thalamic nucleus, anterior 
hypothalamus, dorsal raphe (DR), ventral tegmental area (VTA), LC, and 
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laterodorsal tegmental nucleus (LDT)/pedunculopontine nucleus (PPT) (93-
95). OX1R is also distributed in the peripheral tissues, such as kidney, 
adrenal, thyroid, testis, ovaries, and jejunum. OX2R is expressed in the 
amygdala and BST, paraventricular thalamic nucleus, DR, VTA, and 
LDT/PPT (94, 95). On the other hand, OX2R is abundantly expressed in the 
ARC, TMN, DMH, PVN nucleus, LHA in the hypothalamus, cornu 
ammonis 3 in the hippocampus, and medial septal nucleus (94, 95). OX2R is 
found in adrenal glands, lung, and pituitary (96). The distribution of OX 
receptors is on the whole consistent with the location of the OX axons and 
OX mRNA-expressing neurons. Thus, the distribution patterns of OX1R and 
OX2R coincide in some regions but are distinct and complementary in some 
others. This suggests different physiological roles for each receptor subtype 
(fig. 5). 
 
 
 
 
 
 
 
Fig. 5: Major  projections  of  orexin  neurons.  Circles  show  major  target  
sites  for  orexins.  Included  in  these  are  the  LC  (containing 
noradrenaline,  NA),  TMN  (containing  histamine,  HA),  raphe  nuclei  
(Raphe,  containing  5HT),  VTA  (containing  dopamine,  DA)  and  
PPT/LDT  (containing  Ach).   
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Functions of orexinergic system 
 
The orexins were recognized as regulators of feeding behavior because of 1) 
their exclusive production in the LHA, a region known as the feeding 
center, and 2) their pharmacological activity since intracerebroventricular 
administration of OX induces food intake (8, 9, 97, 98). Supporting the 
physiological relevance of orexin in the control of feeding, ICV 
administration of an anti-orexin antibody or an OX1R selective antagonist 
reduced food intake (98, 99). OX neurons are reciprocally  connected to 
neurons of hypothalamic ARC for feeding regulation. The responsiveness of 
OX neurons to peripheral metabolic cues, such as leptin and glucose, 
suggest that these neurons have important role as a connection between the 
energy homeostasis and vigilance states. Consistent with the dense 
projection of OX neurons to the ARC (83, 84, 100), several studies have 
suggested that the increased food intake following OX-A administration is 
at least partly mediated by activation of NPY neurons in the ARC (100, 
101). Other events involved in orexin-induced feeding behavior include 
inhibition of  proopiomelanocortin (POMC) neurons in the ARC, which are 
thought to play an important role in leptin-mediated inhibition of food 
intake (101). Recent reports also showed that infusions of OX-A into the 
shell of the nucleus accumbens (NAc) increase feeding behavior (102). 
Moreover infusions of the GABAA receptor agonist muscimol into the NAc 
shell strongly induced food intake and simultaneously increased Fos 
expression specifically in OX neurons (103). These findings suggest that 
reciprocal interactions between the OX and limbic systems play a role in the 
regulation of feeding. In addition, the OX system stimulates feeding 
associated glucose utilization in skeletal muscle by activation of 
sympathetic nervous system through acting on the VMH (104). Although 
OX neurons are scarce, they have a profuse projection system to numerous 
brain regions involved in arousal and cortical activation and in sleep-
wakefulness cycle regulation. In recent years it has become clear that these 
neuropeptides are involved in the regulation of many other organic 
functions, such as thermoregulation and neuroendocrine and cardiovascular 
control, whole-body energy expenditure, reward mechanisms as well as in 
the control of the sleep-wakefulness cycle. In particular dense sites of OX 
innervation include the locus coeruleus, DR, periacqueductal gray (PAG) 
and PVN of the thalamus, structures important for regulation of arousal and 
sleep. Indeed, OX deficiency in rodents and humans results in narcolepsy, 
and evidence suggests that OX crucially regulates the transition between 
sleeping and waking (105-109). OX neurons also send relays via the 
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hindbrain and spinal cord to regulate the autonomic and sympathetic 
nervous system (104, 110-112). Additionally, OX neurons innervate many 
regions involved in regulating behavior, including the amygdala, septal area, 
medial preoptic area, and substantia innominata as well as the VTA and the 
NAc, the main components of the mesolimbic dopaminergic (DA) system 
(113, 114). These histological findings suggest that orexins and their 
receptors are likely to play a broad regulatory role in the central nervous 
system and could regulate feeding, autonomic control, sleep, memory, and 
the reward system. Circadian modulation of OX cells is suggested by the 
presence of a small number of direct projections from the suprachiasmatic 
nucleus (SCN) (115), although most of the input is indirect through the 
DMH. In contrast, ascending projections mostly arrive from brainstem 
arousal centres. Histamine neurons in the tuberomammillary nucleus are 
also targets of OX neurones, and the reciprocal interactions between the 
histamine system and OX may have an important role in cortical arousal 
(116). These multifunctional neuropeptides modulate energy homeostasis, 
arousal, stress, reward, reproduction and cardiovascular function. OX 
neurons, in general, have a stimulatory effect on LH neurons, including 
melanin-concentrating hormone (MCH) neurons. Notably, OX neurons are 
rapidly activated by fasting and exhibit leptin-dependent synaptic plasticity 
during fasting. Elevated orexigenic output of the melanocortin system 
promote the activity of corticotropin releasing hormone (CRH)-producing 
neurons in the hypothalamus, which, in turn, can further activate OX 
neurons (117) (Fig 6). 
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Fig. 6: Orexin neurons in the lateral hypothalamic area (LHA) and 
posterior hypothalamus (PH) are anatomically well placed to provide a link 
between the limbic system, systems involved in energy homeostasis and 
monoaminergic and cholinergic neurons in the brain stem. Solid arrows 
show excitatory projections, and broken lines inhibitory ones. Wake-active 
regions, sleep-active regions and REM-active regions are shown by red, 
blue and green boxes, respectively. Orexin neurons promote wakefulness 
through the monoaminergic nuclei that are wake-active. Stimulation of 
dopaminergic centres by orexins can modulate reward systems (purple). 
Peripheral metabolic signals such as leptin, ghrelin and glucose influence 
orexin neuronal activity to coordinate arousal and energy homeostasis. The 
nucleus suprachiasmaticus (SCN), the central body clock, sends signals to 
orexin neurons via the dorsomedial hypothalamus (DMH). The DMH acts 
as a food-entrainable ossilator, and influences orexin neuronal activity. 
Input from the limbic system (amygdala and bed nucleus of the stria 
terminalis (BST)) might regulate the activity of orexin neurons upon 
emotional stimuli to evoke emotional arousal or fear-related responses. 
VLPO, ventrolateral preoptic area; DR, dorsal raphe; GABA, -
aminobutyric acid; LC, locus coeruleus; LDT, laterodorsal tegmental 
nucleus; PPT, pedunculopontine tegmental nucleus; SNr, substantia nigra 
pars reticulata; TMN, tuberomammillary nucleus. 
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Lateral hypothalamic area 
 
The lateral hypothalamic area (LHA) is a large and heterogeneous area with 
several distinct nuclear groups and is one of the most extensively 
interconnected areas of the hypothalamus, allowing it to receive a vast array 
of interoceptive and exteroceptive information and to modulate cognitive, 
skeletal motor, autonomic, and endocrine functions. The LHA merges 
rostrally into the preoptic area and caudally into the ventral tegmental area. 
It borders medially to the dorsomedial, ventromedial, and arcuate nuclei and 
the anterior hypothalamic and medial preoptic areas, and laterally to the 
internal capsule, the optic tract, and more caudal to the subthalamic nucleus. 
There is no doubt that the LHA consists of numerous distinct nuclei (118, 
119), but the function and connectivity of most of these subnuclei has not 
been systematically studied. Generally, the LHA can be divided into 
anterior, tuberal (roughly at the level of the ventromedial hypothalamus) and 
posterior portions based on its efferent connectivity as first described by 
Saper (119). Based on such verification, afferents to the lateral 
hypothalamic area have been demonstrated to originate from various 
cortico-limbic structures such as the prefrontal/orbitofrontal, insular, and 
olfactory cortex, amygdala, hippocampal formation, the shell of the nucleus 
accumbens, and from brainstem structures including most aminergic cell 
groups such as the nucleus of the solitary tract (120, 121). Afferents from 
medial portions of the hypothalamus, although generally sparse, are 
functionally highly significant, as for example, projections from the arcuate 
nucleus POMC/CART and NPY/AgRP neurons (90, 122, 123). 
Furthermore, given its size and structural complexity, there is considerable 
connectivity within the lateral hypothalamic area itself, particularly 
projections from anterior to more posterior portions (85, 90, 122, 123). 
Within the hypothalamus the lateral zone has efferent projections to most 
medial zone nuclei such as the arcuate, paraventricular, dorsomedial, 
ventromedial, and anterior hypothalamic nuclei (120). Another useful 
anatomic guide is the distribution pattern of two well studied neuronal 
populations that express either OX or MCH (118). OX neurons projection 
pattern is equally widespread throughout the brain but, in particular, OX 
neurons have been shown to project to the ARC and PVN nuclei (79, 85). 
MCH neurons project very broadly throughout the CNS (124, 125), and 
similarly MCH receptors are distributed equally broad in the brain. The 
LHA was originally described as a “feeding center” based on findings that 
LHA lesions produced extreme hypophagia (to the point of starvation) while 
electrical stimulation of the LHA promoted food intake even in sated 
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animals (124-129). Furthermore, MCH expression levels increase with 
fasting and are restored to fed levels with leptin injections (130). 
Intracerebroventricular MCH injections increase food intake (131), and 
MCH overexpression leads to obesity and insulin resistance (132), thus 
suggesting that MCH acts as a typical orexigenic neuropeptide that may 
regulate and integrate various aspects of feeding behavior (132). On the 
other hand, OX-A injections into the lateral ventricle increase food intake 
(133) and systemic injection of an OX receptor antagonist decreases food 
intake (134). OX gene expression does not increase by fasting but is 
strongly increased by leptin administration (130, 135, 136). Most neurons in 
the LHA express more than one peptide and in addition may express either 
one of the classical neurotransmitters glutamate or GABA (Fig. 7, 8). 
 
 
 
 
 
 
Fig. 7: Schematic diagrams showing major inputs (top) and outputs 
(bottom) of the lateral hypothalamic area on an outline of the rat brain. 
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Fig. 8: Interactions of lateral hypothalamic neurons with other 
hypothalamic areas and major behavioral, autonomic, and endocrine output 
pathways and functions. This highly simplified diagram does not show the 
relationship with other important hypothalamic nuclei such as the 
dorsomedial and ventral hypothalamic nuclei. Also not shown are the 
massive reciprocal connections from cortex and limbic structures to the 
lateral hypothalamic area. Arrows entering the three nuclei but not 
contacting individual neurons signifies potential input to all the different 
neuron types in that area. Abbreviations: AgRP, agouti-related protein; 
AVP, arginine-vasopressin; CART, cocaine and amphetamine-regulated 
transcript; CRH, corticotrophin-releasing hormone; DYN, dynorphin; 
GABA, gamma-aminobutyric acid; Gal, galanin, Glu, glutamate; MCH, 
melanin-concentrating hormone; NPY, neuropeptide Y; NT, neurotensin; 
ORX, orexin/hypocretin; OT, oxytocin; POMC, proopio-melanocortin; 
TRH, Thyrotropin-releasing hormone; LHA, lateral hypothalamic area; 
PVN, paraventricular nucleus of the hypothalamus; SCN, suprachiasmatic 
nucleus; 3V, third ventricle. 
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Leptin 
 
In 1950 the Jackson Laboratory identified a mouse line displaying profound 
hyperphagia, obesity, infertility and severe hyperglycemia resulting in 
diabetes. Nearly five decades later the genetic deficit underlying this 
phenotype was found to be a mutation on chromosome 6 in the obese (ob) 
gene and its gene product, leptin (137). It is a hormone produced by 
adipocytes and secreted into the circulation. Importantly, leptin is produced 
in proportion to peripheral energy reserves (i.e. fat), so leptin concentration 
indicates how much energy the body has on board (138). The crucial role of 
leptin in energy homeostasis is revealed by the hyperphagic and obese 
phenotypes of leptin-deficient rodents and humans, which are normalized 
with leptin treatment (139, 140). Leptin is thought to act in the CNS to 
regulate food intake and energy expenditure (141, 142).The secretion of 
leptin is reduced during periods of fasting and increased after meals, and is 
influenced by several metabolic and hormonal factors (140). Leptin also has 
an important role in the regulation of glucose homeostasis, reproduction, 
growth, the immune response and motivated behaviors, such as intake of 
food and drugs of abuse and locomotor activity (143-145). Another obese 
mouse was discovered in 1965, with a genetic mutation that mapped to 
chromosome 4: this became known as the db/db mouse (146-148). This 
obese phenotype was not due to lack of circulating leptin but perhaps 
something necessary to transduce the leptin signal and later experiments 
verified that the db gene encodes the long form of the leptin receptor 
(LepRb) (146-149), the only leptin receptor isoform containing the 
intracellular motifs required to convey leptin signals (148,150-152]. The 
central action of leptin is mediated via distributed populations of LepRb-
expressing neurons throughout the brain (153-156). The LepRb is highly 
expressed in hypothalamic nuclei  particularly ARC nucleus, ventro-medial, 
dorso-medial, and LHA. Upon the identification of LepRb much attention 
was devoted to understanding leptin action via the dense populations of 
LepRb-expressing neurons in the ARC and VMH. By comparison, much 
less was known about the nearby population of LepRb-expressing neurons 
in the LHA. In 1998 Elmquist et al. first reported a substantial number of 
LepRb neurons lying within the LHA (154), and an high leptin 
concentrations lead to a reduction of appetite via negative feedback mainly 
via the hypothalamus (157). Over the subsequent decade, many reports 
described leptin effects upon various LHA neuronal populations that altered 
energy homeostasis, but the role of leptin action via LepRb neurons in the 
LHA remained unclear. Neuroanatomical studies have suggested that the 
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majority of leptin’s anti-obesity effects are mediated by leptin receptors 
(LepRb) in the arcuate nucleus (ARC) of hypothalamus (158-160), in which  
leptin regulates the activity of two oppositely acting sets of lepRb-
exspressing neurons by stimulating anorexigenic neurons that express 
POMC and CART, and inhibiting orexigenic neurons that express NPY and 
AgRP. After its binding to LepRb, leptin stimulates a specific signaling 
cascade that results in the inhibition of NPY neurons (161, 162) while 
stimulating POMC neurons (123, 161).These primary targets of leptin action 
communicate with the second-order neurons in other hypothalamic nuclei 
(especially PVN, dorso-medial, ventro-medial and LHA), where peripheral 
information on energy depots is integrated with behavioural, hormonal, and 
nutritional inputs coming from the periphery and higher cortical centres. 
Several hypothalamic neurotransmitters produced in these regions, 
including corticotropin releasing hormone (CRH), thyrotropin releasing 
hormone (TRH), MCH, brain-derived neurotrophic factor (BDNF), 
oxytocin, and OX, are physiologically involved in energy homeostasis. 
Leptin indirectly inhibits or stimulates these peptides, contributing to the 
regulation of energy intake and thermogenesis. Recent papers show that 
leptin modulates also the axonal growth and synaptic plasticity within the 
hypothalamus (6, 7). In particular, leptin increases neurite extension in the 
ARC during mouse perinatal development, thus playing an early trophic role 
within those circuits that will be the target of leptin physiological actions in 
adult life (6). Infact, ARC projections to each of its targets are markedly 
reduced in leptin-deficient Lep ob/ob (ob/ob) mice, and exogenous leptin 
can rescue these projections if administered during neonatal life (although 
not in adulthood) (6). It has been proposed that the leptin surge occurring in 
the perinatal period (163) promotes the maturation of hypothalamic circuits, 
which will be later functionally responsive to the hormone itself (6). The 
data presented by Bouret et al. indicate that distinct LepRb signaling 
pathways are required for normal development of hypothalamic neural 
projections that later convey the effects of leptin on energy balance (164). 
Leptin acts via multiple intracellular signaling pathways, including STAT3, 
ERK, and PI3-K→Akt, to modulate cellular and organismal physiology 
(145). Many data suggest important roles for LepRb →ERK and LepRb 
→STAT3 signaling in initial axonal outgrowth during ARC circuit 
formation. Leptin receptors are members of the cytokine receptor 
superfamily that interact with JAK/STAT via specific intracellular docking 
sites. Leptin's interaction with its receptor causes the activation of JAK2, 
which in turn can lead to the activation of other downstream kinase 
cascades, including MAPK and phosphatidylinositol 3-kinase (PI 3-K). This 
30 
 
activation induces a central signaling pathway that involves activation of 
signal transducer and activator of transcription 3 (STAT3) (151). In 
particular, leptin acts as a trophic factor in the elaboration of cortical growth 
cones by modulating MEK/ERK, PI3K/Akt, and PKC signaling pathways 
that converge in the inhibition of glycogen synthase kinase-3β (GSK3β). 
GSK3β is known to be a target of PI3K/Akt-mediated phosphorylation at 
Ser-9 (165). It is well established that phosphorylation of Ser9 on GSK3 β 
hinhibits its activity and leads to the inactivation of the enzyme which 
results in the reduction of tau phosphorylation (166). Tau is a group of 
neuronal microtubule-associated proteins which stabilize axonal 
microtubules and maintains neuronal processes. Tau plays a key role in 
regulating microtubule dynamics, axonal transport and neurite outgrowth, 
and all these functions of Tau are modulated by site-specific 
phosphorylation. Tau is a phosphoprotein and its phosphorylation negatively 
regulates its ability to stimulate microtubule assembly (167-169). It was 
demonstrated that primed phosphorylation of Tau at Thr 231 by GSK3β 
played a critical role in decreasing Tau’s ability to both bind and stabilize 
microtubules (170). Treatment of cells with lysophosphatidic acid results in 
activation of GSK3β, increased Tau phosphorylation and neurite retraction 
(171, 172).  
 
 
 
 
 
Fig. 9: Leptin signaling patways. 
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Hypothalamic endocannabinoids, orexin and leptin interaction in the 
control of food intake 
 
Feed intake is a critical process for the normal growth and reproduction of 
mammals. Current studies on the regulation of food intake suggest that there 
are many central mediators that control the appetite. In recent years, the 
central regulation of energy balance has become even more fascinating and 
complex with the characterization of new mechanisms of control. The 
process leading to alterations in feed intake result from a complicated 
interplay between a large variety of factors, such as feed availability and 
quality, circulating concentrations of hormones and metabolites, as well as 
physical responses of the gastrointestinal system, all integrated by the CNS 
to yield the final physical act of eating. Although it is the CNS that regulates 
energy homeostasis, the CNS is responding in part to signals produced 
peripherally in proportion to the status of adipose tissue reserves, and in 
response to the presentation and ingestion of feed and the products of 
digestion. The hypothalamus has a central role in the integration of the 
various signals, resulting in activation of feeding or inhibition of feeding 
responses. A major location for the processing of these appetite regulatory 
signals is the ARC nucleus. Both stimulatory and inhibitory signals 
originate from the ARC and influence other secondary appetite neurons 
within the LHA, DMH, VMN, and PVN and subsequently other areas of the 
CNS, with those signals emerging from the LHA-DMH being stimulatory to 
feed intake and those from the VMN and PVN being inhibitory (173). With 
the discovery of leptin and the recent findings in the molecular genetic 
studies of several hypothalamic neuropeptides a new light has been shed in 
the molecular mechanism involving the feeding behavior and energy 
homeostasis. These studies suggested that leptin might diametrically 
regulate the LHA, which had initially been considered as a “feeding center”. 
Leptin administered selectively into the LHA inhibits food intake and 
promotes weight loss in rats. Furthermore, fasting (which decreases 
circulating leptin) and diet-induced obesity (in which neurons no longer 
respond normally to leptin) increase neuronal activation in the LHA — 
these data suggested that leptin normally acts to suppress the LHA “feeding 
center” (174,175). Leptin also may act by suppressing the activity of OX 
neurons, the biosynthesis of OX or both. OX have an important role in the 
hypothalamic central regulation of feeding behavior and many data indicate 
that OX neurons are involved in an appetite regulatory circuit that includes 
the circulating hormone leptin. Patch-clamp measurements in isolated OX 
neurons indicate that leptin can directly decrease the neuronal firing rate and 
intracellular Ca2+ concentrations (176). Recent study also showed that the 
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OX contents in the LH are increased in ob/ob mice. In addition, leptin has 
been shown to directly as well as to indirectly (via the α-MSH pathways 
originating in the ARC) inhibit gene expression for OX (177). Moreover, an 
OX1R-selective antagonist reduced food intake and ameliorated obesity of 
leptin-deficient ob/ob mice (134), suggesting that leptin deficiency at least 
partly activates the orexin pathway to increase food intake. Several studies 
reported a major role of the EC system in this central regulation of food 
intake. More recently, increasing evidence supports the view that the 
activation of the EC system plays important regulatory roles in the control 
of food intake, energy balance and body mass through central and 
peripheralmechanisms at multiple levels including the brain, gastrointestinal 
tract, liver, pancreas, muscle and adipose tissue. The binding of ECs to CB1 
receptors results in increased appetite, weight gain and lipogenesis. In the 
hypothalamus, ECs increase the production of orexigenic neurotransmitters 
and reduce the anorexigenic signals (178). The peripheral signals are able to 
determine changes within the activity of the central EC receptor. 
Nevertheless, if ECs stimulate eating by actions at central CB1 receptors, 
reciprocally, brain levels of ECs are in direct relation to feeding or changing 
nutritional status. Such a negative regulation of the  EC production after 
feeding may be under the control of leptin secreted as an anorexigenic factor 
(2, 179). The notion that leptin and ECs participate in crosstalk was first 
suggested by the observation in mice in which leptin signaling was 
impaired. Impairment of leptin signaling (db/db mice expressing a defective 
leptin receptor), leptin deficiency (ob/ob), and leptin resistance (acquired 
resistance due to diet-induced obesity) in mice showed elevated levels of 
ECs in the hypothalamus and in adipose tissue (5). Central effects of leptin 
result in reduced levels of endocannabinoids due to interference with 2-AG 
synthesis and increased AEA degradation (4, 178). Administration of leptin 
in leptin-deficient ob/ob mice led to significantly down-regulate 
hypothalamic levels of ECs (2). Furthermore CB1 has been shown to 
colocalize with the food intake inhibiting the neuropeptide corticotropin-
releasing hormone in the PVN of the hypothalamus, with melanin-
concentrating hormone in the LH and pre-pro-orexin in the ventromedial 
hypothalamus (178, 180, 181). There is evidence that the LH could be an 
important site for the endocannabinoid action on energy balance. Another 
LH neuronal entity liable to play a significant role in the regulation of 
energy balance, and which could be implicated in the metabolic effect of 
endocannabinoids, is the OX system. That there could be some cross-talk 
between the OX and EC system to regulate energy balance is supported by 
the apparent co-localization of the CB1 and OX-A receptors in the ARC and 
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PVH (182). These new findings on the neuroendocrine mechanisms 
controlling energy homeostasis and body weight show the complexity of 
these integrating systems and the existence of many unravelled mysteries. 
Nevertheless, each mystery unveiled opens new opportunities for the 
development of novel therapies for obesity and nutritional disorders 
(Fig.10). 
 
 
 
 
 
Fig. 10: a,b) Model for mechanisms of endocannabinoid and leptin 
signaling and modulation of GABAergic and Glutammatergic transmission 
in the perifornical LH neurons of the LH. c) Hypothalamic 
endocannabinoids, orexin and leptin interaction in the control of food intake 
with leptin actions and downstream effects in the arcuate nucleus, 
ventromedial hypothalamus (VH) and lateral hypothalamus.  
a b 
c 
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Short-term food deprivation induces a “rewiring” of several hypothalamic 
nuclei that may underlie changes in the release of hypothalamic and 
peripheral orexigenic and anorexigenic mediators. In the ARC, neurons 
expressing pro-opiomelanocortin (POMC) and cocaine and amphetamine 
responsive transcript, on the one hand, and those expressing neuropeptide Y 
(NPY) and the agouti-related peptide (AgRP), on the other hand, undergo 
reciprocal changes in excitatory vs. inhibitory input, thus decreasing the 
activity of the former and increasing the activity of the latter, and facilitating 
food consumption (6,7). Food deprivation-induced enhancement of 
excitatory inputs also occurs on one of the two major subsets of neurons of 
the LH (12), i.e. orexinergic neurons (8, 79). These neurons send projections 
throughout the brain, thereby modulating not only food intake, but also 
more generally arousal and reward (79, 83, 183, 184). All of these changes 
are attenuated by re-feeding, are attributable to reduced leptin levels, and are 
reversed when leptin is administered to food-deprived mice (6, 7, 12). This 
“rewiring” of hypothalamic nuclei is scantily investigated in animal models 
of obesity. Perhaps even more surprisingly, given the prominent role of the 
endocannabinoid system in modulating both inhibitory and excitatory 
neurotransmission, its sensitivity to altered leptin and its dysregulation in 
obesity (4), it is not known if obesity-induced “rewiring” of the 
hypothalamus affects endocannabinoid system and its crucial 
neuromodulatory function. Furthermore, recent papers show that leptin 
modulates axonal growth and synaptic plasticity within the hypothalamus 
(6, 7). Bouret et al. report that dinstinct LepRb signaling pathways are 
required for normal development of hypothalamic neural projections (164), 
but the role of leptin action via LepRb neurons in the LHA remained 
unclear. Leptin acts by modulating MEK/ERK, PI3K/Akt, and PKC 
signaling pathways that converge in the inhibition of glycogen synthase 
kinase-3β (GSK3β). The phosphorylation of Ser9 on GSK3β inhibits its 
activity and leads to the reduction of Tau phosphorylation (166). Tau 
phosphorylation negatively regulates its ability to stimulate microtubule 
assembly (167-169).  
The present study was primarily aimed at assess if obesity-induced rewiring 
of hypothalamic neurons occurs in the LH and its impact on the 
neuromodulatory function of the endocannabinoid system. In particular, we 
investigated if remodeling of orexinergic neuronal wiring also occurs during 
a prolonged nutritional perturbation caused by, or resulting in, leptin 
signalling deficiency, as in ob/ob and HFD mice, respectively, and its 
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impact on endocannabinoid signalling. We will test the hypothesis that the 
activity of orexin neurons could be modulated by a CB1-receptor-mediated 
inhibitory effect on the GABA inhibitory and/or Glutammate excitatory 
projections (by means of DSI and DSE) controlling the activity of the LH 
orexin neurons and the hypothesis that leptin-deficiency modifies the 
distribution of CB1 receptors between excitatory and inhibitory terminals 
leading to a switch from excitatory to inhibitory projections, which would 
alter endocannabinoid-control of neuronal activity. 
 
At this purpose we will provide evidences in order to: 
A. Ascertain the localization of the endocannabinoid system in the LH and 
in particular in the OX circuit.   
 
B. To define the exact localization of CB1 receptor on GABAergic or 
glutamatergic fibers targeting the OX neurons.  
 
C. To define if remodeling of CB1 receptor distribution on 
excitatory/inhibitory inputs onto OX neurons occurs during disorders of 
food-intake.  
 
D. To define if a switch from excitatory to inhibitory wiring dependent 
from leptin deficiency occurs on OX neurons during disorders of food-
intake and its impact on the neuromodulatory function of the 
endocannabinoid system. 
 
Therefore, we employed electrophysiological, immunohistochemical, 
ultrastructural, biomolecular  and biochemical methods to assess the 
changes in endocannabinoid signaling in LH orexinergic neurons and the 
role of leptin deficiency in this rewiring, in ob/ob mice at different postnatal 
ages, and in mice made obese by a high fat diet (HFD). 
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Experimental procedures 
 
Experiments were performed according to the guidelines of the institutional 
ethical code and the Italian (D.L. 116/92) and EEC (O.J. of E.C. L358/1 
12/18/1986) regulations for the care and use of laboratory animals. In our 
study we employed the following animals: 
 
a) Male leptin knockout ob/ob mice (JAK® mouse strain) B6.V-Lepob/J 
and wt leptin gene expressing homozygous siblings, of various ages, 
were obtained from breeding leptin gene heterozygouts, and genotyped 
with PCR. The pups were housed together with their dam up to weaning 
and consumed maternal milk only. After weaning, all these animals 
were fed ad libitum with a standard laboratory regimen (3.5 kcal/g, 
14.5% of energy as fat). 
 
b) Nine week old male C57BL/6J were made obese by being fed 7 weeks 
of high fat diet (n=6; HFD TD97366 Harlan, 4.7 kcal/g: 49% fat, 18% 
protein and 33% carbohydrate). Lean mice received a standard fat diet 
(SFD, n=6; 3.5 kcal/g, 14.5% of energy as fat). Serum leptin 
(Quantikine M; R&D Systems) levels were determined using 
commercial sandwich ELISA assays (B-Bridge International) in 
accordance with the manufacturer’s instructions. All animals were 
maintained on a 12 h light/dark cycle (light off at 9 p.m) and fed ad 
libitum 
 
 
 
Perfusion and preparation of tissue sections 
 
For immunofluorescence and peroxidase based immunohistochemistry all 
the animals (n=10 per group) were deeply anesthetized with a mixture of 
ketamine–xylazine (25 mg/ml ketamine, 5 mg/ml xylazine, 0.1% w/w 
pipolphen in H2O; 1 ml/100 g, i.p.). Animals were then perfused 
transcardially with 0.9% saline for 5 min, followed by 100 ml of fixative 
containing 4% paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, 
for 20 min. At the end of this procedure conducted at a controlled 
temperature of 4°C and constant flow (10ml x min), the brain was 
removed from the skull, post-fixed for 2 hours in the perfusion fluid 
at 4°C, washed in PB and finally soaked for cryoprotection in 30% sucrose 
in PB at 4°C until it sank.  After the time necessary for the brain to sink in 
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the liquid cryopreservation, the same has been frozen rapidly in liquid 
nitrogen and was cut with a Leica CM3050S cryostat (Leica, St. Louis, MO, 
Germany) in serial coronal frozen sections (10 µm-thick) collected onto 
electrostatic charged Menzel Super frost slides (Menzel Thermo Fisher 
Scientific, Germany) in three alternate series. For electron microscopy, the 
fixative contained 3% paraformaldehyde and 0.5% glutaraldehyde and The 
brains for double immunogold histochemistry were cut as 50-µm-thick 
coronal sections by a Leica VTS-1000 Vibratome (Leica, St. Louis, MO, 
Germany).  
For RT-PCR analysis and Lipid extraction and endocannabinoid 
measurement the animals were sacrificed by cervical dislocation and the 
brains were quickly removed. Then the area corresponding to the 
hypothalamus  has been  micro-dissected,  excised,  frozen in liquid 
nitrogen and stored at -80 ° C until the biochemical assay. 
 
 
 
Leptin injection 
 
Recombinant murine leptin (Sigma) was reconstitueted in 10 mM pathogen-
free Tris-HCl buffer pH 7.4 and 300 µl of this solution (10 mg/kg) was 
injected intraperitoneally in adults wt and ob/ob mice. The animals were 
rapidely sacrified or perfused and processed for electrophysiology or 
immunohistochemistry respectively.  
 
 
 
Immunofluorescence and peroxidase based immunohistochemistry 
 
For the single antibody immunoperoxidase procedure, sections were 
incubated with specific normal serum-diluted primary polyclonal antibodies 
of rabbit or guinea pig anti-DAGLα (all supplied from Prof. Mackie with 
respective blocking peptides) or rabbit anti-CB1 (supplied from Prof- 
Mackie or from Chalbiochem, Merck KGaA, Darmstadt, Germany), or goat 
anti-OX-A or anti-MAGL (Abcam Cambridge, UK) or anti-VGAT 
(Synaptic Systems, Goettingen, Germany) or anti-VGluT2 (Synaptic 
Systems, Goettingen, Germany) or anti-MCH (Abcam, Cambridge, UK) 
(range 1:200 - 1:400). Each primary antibody was revealed by specific 
biotinylated secondary anti- IgGs (Vector Laboratories, Burlingame, CA) 
followed by incubation with the avidin-biotin complex (ABC Kit; 
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Vectastain, Vector) and revealed by 3-3’-diaminobenzidine (DAB Sigma 
Fast, Sigma-Aldrich, Louis, MO U.S.A.). For multiple immunofluorescence 
the sections were incubated in a mixture of anti-OX-A combined with 
DAGLα or CB1 or CB1/Synaptophisin or CB1/VGluT2 or CB1/VGAT or 
MAGL/VGAT or MAGL/VGluT2. Multiple immunofluorescence was 
revealed by specific Alexa488/546/350 secondary donkey anti-IgGs. 
Controls of specificity of immunolabeling in multiple fluorescence 
experiments were performed by omission of primary and/or secondary 
antibodies or by preadsorbtion of primary antibodies with respective 
blocking peptides. Since DAGLα or MAGL immunostaining have not 
previously been described in the LH, we also ran single 
immunohistochemistry analyses by using pre-absorption of DAGLα 
antibody with its immunizing peptide or incubation of MAGL antibody with 
brain sections prepared from MAGL-/- mice. In no immunostaining was 
detected in these controls. The sections processed for immunofluorescence 
were examined using confocal laser scanning microscopy (LSM510 Meta, 
Zeiss) or a conventional fluorescent microscope equipped with the 
appropriate filters and equipped with a deconvolution system (Leica 
DMI6000B). Images were acquired using a digital camera (Leica DFC420). 
Image analysis was performed using the Leica MM AF Analisi Offline 
software including the Z-stack acquisition and deconvolution processing 
(Leica, Germany). For quantitative analysis of the ratio of CB1/VGluT2 or 
CB1/VGAT terminals onto OX-A neurons, merged excitatory or inhibitory 
puncta were counted in n=500 orexinergic neurons for each genotype and 
diet group. No labeling was detected in each control performed for reaction 
of multiple immunofluorescence. Quantitative analysis of CB1/VGAT- vs. 
CB1/VGluT2-immunolabeled axon terminals were acquired from 
CB1/VGAT/MCH or CB1/VGluT2/MCH or CB1/VGAT/OX-A or 
CB1/VGluT/OX-A sections in the Z-stack mode and reconstructed by 
application of MMOffline© Leica software for cell imaging and signal 
colocalization counting. n=60±6 OX-A neurons per group at 3, 5 and 9 
weeks of wt, ob/ob, and at 16 weeks of SFD and HFD mice were used. 
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Pre-embedding immunogold-silver labeling 
 
Pre-embedding double immunogold-silver labeling was performed 
according to the procedure of Yi and coworkers (185). Sections of 50µm 
from the LH of three obese (ob/ob or HFD) and three lean (wt or SFD) mice 
were prepared using a VTS-1000 vibratome (Leica, St. Louis, MO, 
Germany). Sections of obese and lean mice were washed in PB, placed for 
15 min in PB containing 0.1% sodium borohydride to inactivate residual 
aldehyde groups in the tissue sections and then washed four times for 10 
min each in PB. Sections were incubated in a blocking solution (2% BSA 
and 0.02% saponin in PBS) for 1 hour and then with the mixtures of two 
primary antibodies from different species at a working dilution of 1:200 in 
the blocking solution overnight at 4°C. Primary antibodies were: 1) a 
mixture of rabbit anti-CB1 and guinea pig anti-DAGLα; 2) a mixture of goat 
anti-OX-A and rabbit anti-CB1; 3) a mixture of goat anti-OX-A and guinea 
pig anti-DAGLα. After 6 washes of 10 min with PBS, sections were 
incubated, for 4 hours in gentle agitation at +4°C, with each first ultrasmall 
gold conjugate secondary antibody of donkey anti-IgG (Aurion, The 
Netherlands), specific for the respective first antibody of the mixture, 
diluted 1:50 in the blocking solution. The secondary antibodies were both 
affinity-purified F(ab')2 fragments of anti-Rabbit IgG (Aurion, The 
Netherlands) or anti-goat or guinea pig (Nanoprobes, NY, USA) conjugates 
to ultrasmall gold particles. Sections were washed with PBS six times for 10 
min and PB two times for 10 min. The enhancement by silver was 
performed with a R-Gent SE-EM kit (Aurion, The Netherlands): sections 
were washed four times for 10 min with ECS (Enhancement Conditioning 
Solution) and then incubated with R-Gent SE-EM silver enhancement 
solution, at room temperature for 90 min shielded from bright light. The 
enhancement was stopped with 0.03 M sodium thiosulfate in ECS for 10 
min. After four washes in ECS for 10 min each and two washes in PB for 10 
min each, sections were incubated with the second secondary antibody 
ultrasmall conjugate donkey anti guinea pig IgG (Aurion, The Netherlands) 
and anti rabbit IgG (Aurion, The Netherlands), specific for the respective 
second primary antibody of each mixture. The second secondary antibody 
was used at a working dilution of 1:50, for 4 hours, at +4°C in agitation. 
Sections were then washed with PBS six times for 10 min and PB two times 
for 10 min. To prevent loss of labeling during the silver enhancement, 
sections were fixed with 2.5% glutaraldehyde in PB for 2 hours at 4° C 
under gentle agitation. After two washes of 10 min in PB, the second silver 
enhancement was repeated with the R-gent SE-EM silver enhancement 
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solution, at room temperature for 60 min shielded from bright light. The 
enhancement was stopped with 0.03 M sodium thiosulfate in ECS for 10 
min. Then, the sections were washed four times in ECS for 10 min each and 
two times in PB for 10 min each. Additional sections were processed in 
parallel as controls in which the mixtures of primary and/or secondary 
antibodies were omitted. No labeling was detected in each control reaction. 
The sections were post fixed with 0.5% OsO4 in PB for 20 min at 4°C, 
dehydrated in an ascending series of ethanol and propylene oxide, and 
embedded in TAAB 812 resin (TAAB, England). During dehydration, 
sections were treated with 1% uranyl acetate in 70% ethanol for 15 min at 
4°C. Ultrathin (60 nm) sections were collected on Formvar-coated single- or 
multiple slot grids and stained with 0.65% lead citrate for 3 min. Electron 
micrographs were taken with the TEM microscope LEO 912AB (Zeiss, 
Germany). 
 
 
 
Pre-embedding immunogold labeling 
 
A double pre-embedding immunogold labeling with gold particles of 6 and 
10 nm was applied on 50µm vibratome sections, cut perpendicularly to the 
surface of the sections, of the LH of obese and lean mice. Sections were 
pretreated with PB containing 0.1% sodium borohydride for 1 min, washed 
with PB three times for 15 min once and exposed to a blocking solution 
with 5% normal donkey serum and 0.1% saponin for 2 hour at room 
temperature under gentle agitation. Sections were exposed to the same 
mixtures of two primary antibodies from different species as used in the pre-
embedding immunogold-silver labeling: 1) a mixture of rabbit anti-CB1 and 
guinea pig anti- DAGLα; 2) a mixture of goat anti-OX-A and rabbit anti-
CB1; 3) a mixture of goat anti-OX-A and guinea pig anti-DAGLα. The 
sections were incubated in agitation for 24 hours at 4°C with a mixture of 
primary antibodies diluted 1:100 in the blocking solution with 0.02 % 
saponin as detergent in order to enhance antibody penetration. Then the 
sections were washed in PB for 1 hour (six washes of 10 min once), at room 
temperature under gentle agitation. Then sections were incubated in 
agitation overnight at +4°C in a mixture of gold conjugated secondary 
antibodies diluted 1:30 in blocking solution with 0.02 % saponin and 
specific for the mixture of the primary antibodies: 1) a mixture of donkey 
anti-rabbit IgG-gold of 10nm and anti-goat IgG-gold of 6nm specific to 
reveal CB1 and DAGLα, respectively ; 2) a mixture of donkey anti-goat 
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IgG–gold of 10nm and anti-rabbit IgG-gold of 6nm specific to reveal OX-A 
and CB1, respectively; 3) a mixture of donkey anti-goat IgG-gold of 10nm 
and anti-guinea pig IgG of 6nm specific to reveal OX-A and DAGLα, 
respectively. All the secondary antibodies were obtained from Aurion (The 
Netherlands). Sections were washed with PBS four times for 10 min and PB 
two times for 10 min with gentle agitation. Additional sections were 
processed in parallel as controls by omitting the mixtures of either both or 
one of the primary antibodies of the mixture and/or of the secondary 
antibodies. No labeling was detected in each control reaction. Sections were 
then treated with 0.5% OsO4 in PB for 10 min at 4°C, dehydrated in an 
ascending series of ethanol and propylene oxide, and embedded in TAAB 
812 resin (TAAB, England). During dehydration, sections were treated with 
1% uranyl acetate in 70% ethanol for 15 min at 4°C. Ultrathin (60 nm) 
sections, carried out perpendicularly to the surface of 50 µm vibratome 
sections, were collected on Formvar-coated single- or multiple-slot grids 
and 0.65% lead citrate for 3 min. Electron micrographs were taken with the 
TEM microscope LEO 912AB (Zeiss, Germany). 
 
 
 
 
Quantitative analysis of immunogold labeling 
 
The relative abundance of CB1 inhibitory and excitatory inputs to OX-A 
cells was calculated through unbiased electron microscopy analysis applied 
to sequential silver-enhanced OX-A/CB1 preembedding immunogold on 
ultrathin sections of pre-weaned, post-weaned and adult ob/ob mice and 
adult HFD mice as compared to the respective wt and SFD mice (n=3 per 
group). Through sequential silver-enhanced double immunogold the 
expression of OX-A antigen was unequivocally discriminate showing the 
larger size than CB1 because its ultra-small gold conjugates antibody was 
enhanced twice while the anti-CB1 second ultra small gold conjugates 
antibody was enhanced only once (see the pre-embedding immunogold-
silver labeling method for details). In these experiments the inhibitory 
synapses were identified by their symmetrical morphology and excitatory 
synapses by their asymmetrical morphology. Metal particles were counted 
only in presynaptic and postsynaptic profiles that possessed clearly visible, 
anatomically defined symmetrical or asymmetrical synapses. Selected 
boutons of 5 orexinergic neurons per animal were followed through 24 
consecutive LH serial ultrathin sections (n=3 mice per group). According to 
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the synaptological method applied in the LH by Horwath and Gao (12) we 
randomly sampled every element of the analysis as the bouton at high power 
magnification, the orexinergic-immunoreactive perikarya and the plane of 
each transected OX-A cell. In this assesment 20 CB1-expressing boutons 
contacting OX-A soma were analyzed per each animal (an average of 4 
CB1-expressing boutons per neuron). Moreover, from a different ribbon of 
24 consecutive LH serial ultrathin sections we analyzed 10 CB1-expressing 
axo-dendritic boutons to following 4 orexinergic neurons. 
 
 
 
Pre-proorexin mRNA quantification by RT-PCR analysis 
 
Tissue samples from LH were dissected, from three animals for each group, 
and collected in RNA later (Invitrogen) following manufacturer’s 
instructions and were homogenized in 1.0 ml of Trizol® (Invitrogen). Total 
RNA was extracted according to manufacturer recommendations, dissolved 
in RNAase-free water, and further purified by spin cartridge using the 
PureLink-micro RNA purification system (Invitrogen). Total RNA was 
dissolved in RNA storage solution (Ambion), UVquantified by a Bio-
Photometer® (Eppendorf), and stored at −80°C until use. RNA aliquots (6 
µg) were digested by RNAse-free DNAse I (Ambion DNA-free™ kit) in a 
20 µl final volume reaction mixture to remove residual contaminating 
genomic DNA. After DNAse digestion, concentration and purity of 
RNAsamples were evaluated by the RNA-6000-Nano® microchip assay 
using a 2100 Bioanalyzer® equipped with a 2100 Expert Software® 
(Agilent) following the manufacturer’s instructions. For all samples tested, 
the RNA integrity number was greater than 7 relative to a 0–10 scale. One 
microgram of total RNA, as evaluated by the 2100 Bioanalyzer, was 
reverse-transcribed in cDNA and analyzed as previously described (186). 
Optimized primers for SYBR-green analysis (GenBank accessions: 
Hypocretin Hcrt-NM_010410, hypoxanthine guanine phosphoribosyl 
transferase Hprt-NM_013556) and optimum annealing temperatures were 
designed by Allele-Id software version 7.0 (Biosoft International) and were 
synthesized (HPLC-purification grade) by MWG-Biotech. Relative gene 
expression calculation, corrected for PCR efficiency and normalized with 
respect to the reference gene Hprt was performed by the IQ5 software, as 
previously described. 
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Electrophysiology 
 
Miniature Inhibitory Post Synaptic Currents (mIPSCs) were recorded in 
OX-A neurons of the lateral hypothalamic area from ob/ob, their wt siblings 
and c57bl/6 mice (n of neurons/n of mice: 31/15, 27/9, 8/7, respectively). 
Two developmental stages were investigated: before weaning (range P18-
23, average P21), and after weaning (range P30-39, average P34). In a 
subset of experiments, ob/ob and wt mice were fasted for 24 hr and received 
a single injection of recombinant leptin (50 µg i.p. at the beginning of food 
deprivation) before mIPSCs recording (n of neurons/n of mice: 13/4, 12/4, 
ob/ob and wt, respectively). Spontaneous Inhibitory Post Synaptic Currents 
(sIPSCs) were recorded after weaning (range P27-39, average P32,) in 
29/13 ob/ob and 26/15 wt mice. Mice were anesthetized by inhalation of 
ether and depth of anesthesia was judged by lack of a righting reflex. The 
brain was perfused transcardially with ice-cold dissection media (DM), and 
the cerebral hemispheres quickly removed, placed in ice-cold DM and 
reduced to blocks. DM consisted of (in mM) 220 sucrose, 26 NaHCO3, 1.23 
NaH2PO4, 2.5 KCl, 6 MgCl2, 1 CaCl2, and 10 glucose, equilibrated with 
95% O2/5% CO2. Hypothalamic coronal slices (200 µm thick) were cut in 
ice-cold DM and later collected in a holding chamber at 32oC for 45 min in 
artificial cerebrospinal fluid (ACSF) consisting of (in mM) 122 NaCl, 26 
NaHCO3, 1.23 NaH2PO4, 2.5 KCl, 2 MgCl2, 2 CaCl2, 1 Na-ascorbate, 3 Na-
pyruvate and 10 glucose, equilibrated as above. Slices were subsequently 
transferred in a recording chamber perfused at 2-3 ml/min with ACSF at 
room temperature. Excitatory inputs were blocked with 10 µM NBQX and 
CPP (Sigma). At the end of each recording, 30 µM bicuculline (Sigma) was 
added to the bath, to confirm the inhibitory nature of the recorded synaptic 
activity. When appropriate, CB1-Receptors were activated by adding 5 µM 
WIN55,212-2 mesylate (WIN, Tocris), or blocked with 4 µM AM251 (AM, 
Tocris). Whole-cell recordings were performed with an Axopatch 200B 
amplifier (Axon Instruments), under a custom-made microscope equipped 
with an infrared video camera (Hamamatsu) and differential interference 
contrast optics. Neurons were functionally identified as orexinergic by 
recording, in current clamp mode, their typical responses to injected current 
pulses. Neurons were then voltage-clamped at -70 mV and the activity of 
inhibitory inputs recorded in the presence (mIPSC) or absence (sIPSC) of 
1µM TTX (Sigma). With no TTX the pre-synaptic spiking activity was 
present and thus IPSCs due to both the stochastic and the spontaneous 
action potential-evoked GABA release were recorded. sIPSCs recording 
was performed when testing the effect of WIN and AM on CB1 receptors. 
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Recording electrodes (2-5 MΩ) were made with borosilicate glass (Warner 
Instruments) and filled with (in mM) 145 KCl, 10 HEPES, 0.2 EGTA, 2 
Mg-ATP, 0.5 Na-GTP, pH 7.4 with KOH. Signals were filtered at 10 kHz 
by pClamp 9.2 and digitized at 20 kHz (Digidata 1322A, Axon 
Instruments). Series resistance (<30 MΩ in all analyzed recordings) and 
whole-cell capacitance were not compensated. The recording was 
terminated if series resistance changed more than 20%. To study 
Depolarization-induced Suppression of Inhibition (DSI), sIPSC were 
recorded before and after a step depolarization (5 s) from -70 to 0 mV. DSI 
was calculated as the sIPSC frequency measured in time intervals of 5 s 
after the depolarization and made relative to the frequency during 5 seconds 
before the depolarization. In each experiment, the responses to two 
successive depolarizations (separated by 90 s) were averaged together. In a 
subset of cells, DSI was tested also 4-5 minutes after the addition of 4µM 
AM. All measurements were performed at least 5 minutes from the 
establishment of the whole-cell, to let the cytosol equilibrate with the 
recording solution. The frequencies of mIPSCs and sIPSCs were measured 
over a 1 minute recording. The effect of AM and WIN on sIPSCfrequency 
and amplitude was measured 4-5 minutes after the addition of the drugs. 
Data were analyzed with Clampfit 9.2 (Axon Instruments). A subset of 17 
neurons was injected with 2% FITC-Neurobiotin (Vector Lab) through the 
recording electrode. At the end of the recordings, the slices were fixed in 
4% paraformaldheyde in 0.1M PB for 1h and kept in PB until they were 
incubated in a mixture of goat anti-OX-A/ rabbit anti-MCH primary 
antibodies (Santa Cruz Biotechnology, CA USA), labeled with anti-rabbit 
Alexa546/antigoat Alexa350 secondary antibodies. 
 
 
 
Lipid extraction and endocannabinoid measurement 
 
Tissue samples from the LH were homogenized in 5 volumes of 
chloroform/methanol/Tris HCl 50 mM (2:1:1 by volume) containing 10 
pmol of d8-AEA and 50 pmol of d5-2AG19. Homogenates were centrifuged 
at 13,000 g for 16 min (4oC), the aqueous phase plus debris were collected 
and four times extracted with 1 vol of chloroform. The lipid-containing 
organic phases were dried down and pre-purified by open bed 
chromatography on silica columns eluted with increasing concentrations of 
methanol in chloroform. Fractions for AEA and 2-AG measurements were 
obtained by eluting the columns with 9:1 (by vol.) chloroform/methanol and 
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then directly analyzed by liquid chromatography-atmospheric pressure 
chemical ionization-mass spectrometry (LC-APCIMS). LC-APCI-MS 
analyses were carried out in the selected ion monitoring (SIM) mode, as 
described (2), using m/z values of 356 and 348 (molecular ions +1 for 
deuterated and undeuterated anandamide), 384.35 and 379.35 (molecular 
ions +1 for deuterated and undeuterated 2-AG). AEA and 2-AG levels were 
therefore calculated on the basis of their area ratios with the internal 
deuterated standard signal areas, their amounts in pmols normalized per mg 
of lipids and compared by ANOVA followed by the Bonferroni’s test. 
 
 
 
Statistical analyses 
 
Data are expressed as mean s.e.m. A repeated two-way ANOVA was 
performed using SPSS version 8.2. Student’s or Bonferroni two tail t test 
were used to judge statistical significance between groups (P<0.05). 
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The endocannabinoid system is expressed in OX-A neurons 
 
The distribution of CB1 receptors was recently determined in the LH of 
adult mice (187). We conducted multiple immunofluorescence studies to 
determine the distribution of other key elements of the endocannabinoid 
system in the LH of pre-weaned (i.e. 3 weeks, range: P19-23), weaned (5 
weeks, range: P28-36) and adult (9 weeks old) mice (n=6 per group). First, 
using bright-field and fluorescence microscopy, as well as confocal laser 
scanning microscopy, we studied the expression of diacylglycerol lipase-α 
(DAGLα), the enzyme primarily responsible for the generation of 2-AG, in 
the LH. DAGLα-immunoreactivity was clearly detected on punctate 
structures corresponding to neuronal profiles in the LH (Fig 11). 
Subsequently, we identified, by double DAGLα/OX-A 
immunofluorescence, orexinergic neurons expressing the 2-AG synthesizing 
enzyme (Fig. 12a) and observed, by means of triple CB1/OX-
A/monoacylglicerol lipase (MAGL) immunofluorescence, the expression of 
CB1 receptors and of the 2-AG degrading enzyme, MAGL, in the neuropil 
surrounding OX-A neurons (Fig. 12b, c). MAGLimmunoreactivity was 
clearly detected on punctate structures surrounding neuronal profiles in the 
LH (Fig. 11). When these experiments were quantified, we determined that 
DAGLα was detected post-synaptically in 68.5±8.4% of OX-A neurons 
receiving MAGL/CB1-bearing inputs. Using double immunogold electron 
microscopy, we confirmed that in lean and obese mice (n=3 per group), OX-
A expressing neurons also expressed DAGLα, the corresponding 
immunoreaction product typically being concentrated in the cytoplasm just 
beneath the somatodendritic cell membrane (Fig. 13a-d arrowheads; Fig. 
14a-c and e). In these neurons, most OX-A gold particles accumulated in 
dense vesicles (Fig. 13 a-b,e-f arrows; Fig. 14 c-d) in the cytoplasm of LH 
neurons, with a few being dispersed in low density vesicles and 
intracellularly around the endoplasmic reticulum or Golgi membrane. In the 
same OX-A neurons, DAGLα gold particles were mostly located near the 
internal surface of the plasma membrane (Fig. 13 a-b, arrowheads; Fig. 14 
c,e). In the neuropil, labeling for DAGLα was also found in dendritic spines 
and CB1/DAGLα immunolabeling revealed a typical DAGLα expression 
selectively apposed to CB1-expressing terminals both in axo-somatic (Fig. 
13 c,d) and in axo-dendritic asymmetric and symmetric synapses (Fig. 14 
a,b). These data were obtained by preembedding double immunogold 
labeling of secondary antibodies conjugated with ultra small gold particles, 
revealed by two sequential steps of silver-enhancement according to the 
procedure of Yi et al (185) (Fig. 13), or using a preembedding double 
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immunogold labeling with gold particles of 6nm and 10nm (Fig. 14). 
Controls of antibody specificity were performed for both immmunogold 
methods by omission from the incubation mixture of either primary or 
secondary antibodies. No signal was observed in all performed controls 
obtained after omission of primary antibodies and after omission of 
secondary antibodies. DAGLα immunogold distribution was quantitatively 
evaluated in the DAGLα/OX-A double-immunolabeled LH of adult lean 
and obese mice (Fig. 15). The distribution was quantified after 
normalization to µm of plasma membrane of orexinergic neurons, since in 
the LH the enzyme is mainly expressed near the somatodendritic 
cytoplasmic surface of the plasma membrane, in agreement with previous 
findings in other brain regions (188, 189). 
 
 
 
2-AG levels are upregulated in orexinergic neurons of ob/ob mice and 
mice with HFD-induced Obesity 
 
LH concentrations of 2-AG were measured by isotope-dilution LC/MS mass 
spectrometry in 3, 5 and 9 weeks old ob/ob vs. wt mice and in adult (16 
weeks old) mice after 7 weeks of HFD vs. Standard Fat Diet (SFD) (n=6 per 
group). 2-AG levels in the LH from 9 week old ob/ob mice were increased 
compared to 5 and 3 week old ob/ob mice. No difference was observed 
between 16 week old HFD mice and 9 week old ob/ob mice. Thus, a 
statistically significant increase of 2-AG was observed only in adult obese 
mice, either ob/ob or HFD, compared to the respective lean mice (Fig. 16 
a,b). No differences were found between adult ob/ob or HFD mice and their 
lean counterparts for AEA levels (data not shown). Concurrently with the 
increase of 2-AG levels, a significant elevation of DAGLα 
immunoreactivity (DAGLα–ir) was observed in LH neurons of adult obese 
(ob/ob and HFD) mice compared to matched lean controls and younger 
mice, as assessed by densitometric analysis (Fig. 16c,d) carried out by 
comparing DAGLα staining in slides adjacent to those processed for 
DAGLα/OX-A. 
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Obesity is accompanied by increased pre-proorexin mRNA expression 
in the LH and increased OX-A signaling in the arcuate nucleus 
 
To examine the consequences of altered endocannabinoid control over 
orexin signaling in obese mice, we measured the expression of pre-
proorexin mRNA in the LH of adult and young ob/ob and wt mice by 
quantitative RT-PCR (n=6 mice per group). We found that pre-proorexin 
mRNA levels in the LH are increased in adult obese mice (Fig. 17a). By 
contrast, OX-A-ir in the soma of LH neurons, assessed by densitometric 
analysis, did not significantly differ between adult obese mice (ob/ob mice 
at all ages and adult HFD mice) and the respective controls (Fig. 17 b). 
However, a significant increase of OX-A immunoreactivity was found in the 
orexinergic projections to the ARC in 5 and 9 week old ob/ob mice as well 
as in adult HFD mice (Fig. 17c).  
 
 
CB1–expressing fibers innervating orexinergic neurons are rearranged 
during obesity 
 
An overall increase in immunoreactivity for the GABAergic marker, 
VGAT, vs. the glutamatergic marker, VGluT2, was observed in the LH of 
post-weaning obese mice as compared to lean mice of the same age. When 
we quantified CB1-expressing fibers, a statistically significant difference in 
the distribution of CB1 between excitatory (i.e. VGluT2-expressing) and 
inhibitory (i.e. VGAT-expressing) inputs onto OX-A neurons was observed 
when comparing the LH of lean mice at pre-, post-weaning and adult age, or 
of SFD mice, to that of age-matched ob/ob or HFD obese mice (Fig. 18a-d). 
By contrast, no difference in the general intensity of CB1-ir projections to 
OX-A neurons was observed between different ages of lean vs. obese mice. 
This was documented by densitometric analysis of CB1 staining in afferent 
fibers to OX-A neurons, the orexinergic nature of which was established in 
adjacent double-labeled CB1/OX-A sections (Fig. 19a,b). Moreover, the 
percentage of CB1- immunopositive afferents to OX-A neurons was 
calculated relative to the total number of synaptophysin positive axon 
terminals and there was no difference between lean and obese mice by 
genotype, diet or age (Fig. 19c,d). Quantitative analyses were carried out to 
assess the abundance of CB1/VGAT- vs. CB1/VGluT2-immunolabeled 
axon terminals in apposition to OX-A perikarya, (n=200 cells per LH; n=3 
mice per group). This experiment revealed that in post-weaning and adult 
ob/ob or obese HFD mice CB1/VGAT inputs significantly outnumbered the 
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excitatory ones, contrary to the condition in the matched lean mice, where 
CB1/VGluT2 terminals were more abundant. Interestingly, no difference 
was found between the number of CB1/VGAT vs. CB1/VGluT2- expressing 
inputs in pre-weaning (3 weeks old) wt or ob/ob mice (Fig. 20). Finally, 
using double VGluT2/MAGL or VGAT/MAGL immunofluorescence, we 
observed that the 2-AG degrading enzyme, MAGL, was localized 
preferentially to LH inhibitory terminals compared to excitatory afferents 
onto OX-A neurons of adult obese HFD and ob/ob mice. The opposite 
situation was observed in lean controls (Fig. 21). The relative abundance of 
CB1-expressing inhibitory and excitatory inputs onto OX-A cells was 
further investigated through unbiased electron microscopic analysis. The 
analysis was applied to LH CB1/OX-A double immunogold labeled 
ultrathin sections of pre-weaned, weaned and adult ob/ob mice and adult 
HFD mice and compared to the respective wt and SFD mice (n=3 per 
group). In these blinded experiments, we identified inhibitory synapses by 
their symmetrical morphology and excitatory synapses by their 
asymmetrical morphology. Selected boutons of 5 orexinergic neurons per 
animal (n=3 mice per group) were followed through 24 consecutive LH 
serial ultrathin (60 nm) sections. According to the synaptological method 
used by Horvath and Gao3, we randomly sampled every element of the 
analysis as the bouton at high power magnification, the orexinergic-ir 
perikarya and the plane of each transected OX-A cell. Twenty CB1-
expressing boutons contacting the soma of OX-A neurons were analyzed for 
each animal (i.e. an average of four CB1-expressing boutons per neuron). 
Furthermore, since the boutons contacting the dendritic spine proximal to 
the soma provide a further measure of the overall excitation/inhibition 
balance (given that a high number of synaptic inputs are received by 
proximal dendrites), we also analysed ten CB1-expressing axo-dendritic 
boutons for each mouse from another 24 consecutive LH ultrathin sections, 
different from those used for counting perisomatic CB1-expressing boutons. 
In post-weaning and adult ob/ob mice and in adult HFD mice, CB1-
symmetric (inhibitory) synapses robustly outnumbered CB1-asymmetric 
(excitatory) contacts both in perisomatic and dendritic compartments. 
However, in pre-weaning ob/ob and wt mice an equivalent number of CB1-
inhibitory and CB1-excitatory synapses were found in both perisomatic 
(Fig. 22a-d) and dendritic compartments (Fig. 22e-h). Finally, when 
analyzed as number of boutons per µm of plasma membrane, CB1-
expressing boutons were found to be predominantly symmetric in the OX-A 
perikarya of adult ob/ob and HFD mice, as opposed to them being 
predominantly asymmetric in lean mice (Fig. 23). 
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Functional evidence for the stronger inhibitory innervation of ob/ob 
orexinergic neurons 
 
To determine if our anatomical observation of a stronger inhibitory 
innervation of ob/ob orexinergic neurons had a functional consequence we 
performed whole-cell voltage-clamp recordings of miniature Inhibitory Post 
Synaptic Currents (mIPSCs) in neurons of the LH/perifornical area from 
murine brain slices at two developmental stages: before (3 weeks of age, n = 
10 mice) and after (5 weeks of age, n = 7) weaning. mIPSCs are synaptic 
currents caused by the stochastic release of GABA when sodium-dependent 
action potentials are blocked (1 µM TTX in our case, with ionotropic 
glutamate receptors blocked by 10 µM CPP and NBQX) and provide a good 
estimate of the number of functional inhibitory inputs. In the 
LH/perifornical area about 70% of the neurons express orexins A or B. 
These neurons show a characteristic electrophysiological response to 
injected current, i.e.: 1) a tonic, non-adapting repetitive spiking evoked in 
response to a suprathreshold depolarizing pulse, 2) a rectifying potential 
change evoked in response to hyperpolarizing pulses, and 3) an abortive 
spike evoked in response to a sub-threshold depolarizing pulse (190). For 
our experiments we selected those neurons that showed at least two of the 
above responses, and confirmed the validity of these criteria in a subset of 
17 orexinergic neurons (identified functionally) filled with neurobiotin 
through the recording electrode. With glutamate inputs blocked, we found 
no difference in the mean resting membrane potential of neurons from ob/ob 
and wt mice of the same age. Pooling data together from ob/ob and wt of the 
same age, a statistically significant difference was found in resting 
membrane potential between 3 vs 5 week-old neurons (- 52.6 ± 1.96 mV, n 
= 12, and -44.0 ± 1.08 mV, n = 44, 3 and 5 weeks respectively, P < 0.005). 
The mean input resistance was 154 ± 8.2 MΩ (n = 51), with no difference 
between ob/ob and wt mice at any developmental stage. With a high 
concentration of KCl in the recording solution and recording at a holding 
potential of -70 mV, a chloride-mediated mIPSC appears as an inward 
current (negative deflection on the recording trace). Before weaning, no 
difference was observed in mIPSC frequency betweeen ob/ob and wt 
neurons (0.8 ± 0.28 Hz, n = 8 and 0.8 ± 0.29 Hz, n = 5, ob/ob and wt, 
respectively). Interestingly, and consistent with our morphological data of 
more inhibitory synapses, in weaned ob/ob mice the mean mIPSCs 
frequency of orexinergic neurons was significantly higher than that of wt 
neurons (4.0 ± 0.74 Hz, n = 10; 1.6 ± 0.83 Hz, n = 10, in ob/ob and wt mice, 
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respectively, P < 0.05), and it was also higher than that of pre-weaning 
ob/ob neurons (P < 0.005) (Fig.24).  
 
 
 
Modulation of inhibitory synaptic activity onto orexinergic neurons by 
CB1 
 
We have presented morphological evidence for a higher expression of CB1 
receptors in inhibitory terminals of ob/ob orexinergic neurons compared to 
their wt siblings. Thus we expected the CB1 agonist, WIN55,212-2 (WIN), 
to depress inhibitory synapses more effectively in ob/ob than in wt 
orexinergic neurons from 5 week old mice. To test this prediction we 
recorded spontaneous inhibitory activity in the absence of TTX. In this 
condition spontaneous action potentials are present, and thus two 
populations of IPSCs are simultaneously recorded, collectively named as 
“spontaneous Inhibitory Post Synaptic Currents” (sIPSCs): one population 
that is caused by the purely stochastic exocytosis of the neurotransmitter 
(which corresponds to mIPSCs), and a second one, evoked in response to a 
spontaneous pre-synaptic action potential. Since the activation of CB1 
receptors is known to depress the action potential-evoked Ca2+ influx (22, 
48), underlying synaptic vesicle release, sIPSCs may provide a more 
comprehensive measure of the effect of CB1 activation on synaptic 
transmission than just measuring mIPSCs. Similarly to mIPSCs, control 
sIPSC frequency was higher in post-weaning ob/ob orexinergic neurons 
than in wt neurons. Bath application of WIN (5 µM) reduced the frequency 
of sIPSCs both in ob/ob and in wt, although in the latter group the effect did 
not reach statistical significance (ob/ob: control condition 6.0 ± 1.4 Hz, 
WIN 1.5 ± 0.3 Hz, n = 9, P < 0.01; wt: control condition 4.7 ± 1.99 Hz, 
WIN 1.9 ± 0.84 Hz, n = 9, P > 0.05; Fig. 25). To better estimate a possible 
differential effects of WIN on sIPSC frequency between the two groups of 
neurons, for each experiment sIPSC frequency after WIN was normalized to 
sIPSC frequency before WIN. When data were expressed in this manner, the 
average inhibition was significantly larger in ob/ob compared to wt neurons 
(ob/ob sIPSC frequency after WIN relative to control: 33.1 ± 6.28%, P < 
0.001; wt: 57.1 ± 8.04%, P < 0.001; difference between the two groups 
significant at P < 0.05). Two pieces of evidence are in favor of a CB1-
mediated mechanism of action for WIN. First, the reduction of sIPSC 
frequency was not accompanied by a statistically significant reduction of 
their amplitude (relative ob/ob sIPSC amplitude with WIN: 89.5 ± 10.69%, 
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n = 9, P = 0.2; wt: 83.84 ± 8.04% n = 9, P > 0.1; absolute values in Fig. 25). 
This suggests that the primary site of WIN action was presynaptic, in 
agreement with the characteristic pre-synaptic location and function of CB1 
receptors. Secondly, in the presence of the selective CB1 blocker AM251 (4 
µM), WIN failed to significantly reduce sIPSC frequency (relative ob/ob 
sIPSC frequency with AM+WIN: 76.7 ± 9.67%, n = 6, P > 0.05; wt: 76.7 ± 
14.11%, n = 4, P > 0.1; Fig. 26a). The application of AM251 alone did not 
affect sIPSC frequency, either in ob/ob neurons or their wt siblings (Fig. 
26a). Finally, neither AM alone nor AM+WIN modified sIPSC amplitude 
(Fig. 26b). 
Therefore, we have that ob/ob orexinergic neurons receive a strong 
inhibitory innervation which can be depressed by WIN, acting through 
presynaptic CB1 receptors. We have also shown that the same type of 
neurons express higher levels of DAGLα, which is central in the production 
of the endocannabinoid 2-AG, and that 2-AG itself is present at a higher 
concentration in the LH of ob/ob mice as compared to wt mice. Thus, it is 
likely that ob/ob orexinergic neurons, when stimulated, may release 2-AG, 
which in turn acts retrogradely on CB1-expressing inhibitory inputs to 
reduce their activity (a possible positive feed-back mechanism on the firing 
of ob/ob orexinergic neurons). A well known method to investigate this 
phenomenon is by evoking a Depolarization-induced Suppression of 
Inhibition (DSI). In a previous study examining orexinergic neurons from 
the LH of wt lean mice this type of retrograde inhibition by 
endocannabinoids was not observed (191). Interestingly, in the same study, 
a clear inhibitory effect was described on excitatory inputs (a negative feed-
back mechanism on the firing of orexinergic neurons). These results can be 
reconciled by our present morphological observations of greater CB1 
expression on the excitatory innervation of these neurons in wt and SFD 
lean mice. To test the hypothesis that DSI is increased in orexinergic 
neurons of ob/ob mice (5 weeks of age), we briefly (5 s) depolarized these 
neurons from -70 to 0mV and measured the frequency of sIPSCs before and 
after the depolarization. We found a significant 25-30% frequency reduction 
in ob/ob orexinergic neurons after the depolarization (frequency 5 and 10 s 
after the depolarization relative to 5 s before: 71% ± 0.05 and 74% ± 0.05, n 
= 11, P < 0.001; Fig. 27. Absolute values 5 s before and after the 
depolarization: 11.4 ± 3.33Hz and 8.5 ± 2.58Hz, P < 0.05). The DSI was: 1) 
short-lived, since it lasted about 10 seconds, by which time sIPSCs 
frequency had recovered to control values; and 2) mediated by the release of 
endocannabinoids acting at CB1 receptors, since, when repeating the 
experiment in the presence of AM251, DSI was not observed (frequency 5 
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and 10 s after the depolarization relative to 5 s before: 108% ± 0.13 and 
90% ± 0.05, n = 11, P > 0.5 and > 0.1, respectively; Fig. 27. Absolute values 
5 s before and after the depolarization: 3.6 ± 1.12 Hz, 3.4 ± 0.99 Hz, n = 11, 
P > 0.1). 
 
 
 
The shift from excitatory to inhibitory CB1-expressing inputs onto  
OX-A neurons, and its stimulation of orexin release, are reversed by 
leptin administration in ob/ob mice 
 
To test whether the altered synaptology of OX-A neuronal perikarya in adult 
obese mice is due to leptin deficiency or resistance, an analysis of the 
synaptic organization of these neurons was performed again in 9 week old 
wt and ob/ob mice, after a single injection of recombinant leptin at the 
beginning of 24h food deprivation. A general increase in immunoreactivity 
for VGluT2 and a decrease in VGAT immunoreactivity were observed in 
the LH of ob/ob mice after leptin injection, resembling the pattern observed 
in wt mice. This effect was accompanied by a shift of CB1 expression from 
inhibitory back to excitatory axon terminals (Fig. 28), as assessed by 
quantitative analysis of the abundance of CB1/VGAT-expressing vs. 
CB1/VGluT2-expressing axon terminals in close proximity to OX-A 
perikarya (Fig. 29). These leptin-induced morphological changes were 
paralleled by functional changes in inhibitory signaling onto orexinergic 
neurons. In fact, when we recorded mIPSCs from orexinergic neurons in 5 
week old ob/ob and wt mice 24 hr after a single injection of recombinant 
leptin, we found no difference between ob/ob and wt mice (Fig. 30). This 
contrasts to what we observed in untreated animals, where ob/ob neurons 
had a higher mIPSC frequency. Specifically, after leptin administration, 
mIPSC frequency of ob/ob neurons was indistinguishable from the low level 
observed in wt neurons (ob/ob mIPSCs frequency: 1.35 ± 0.52 Hz, n = 13; 
wt: 1.71 ± 0.76 Hz, n = 12, P > 0.5). Finally, the above leptin treatment also 
reversed the changes in OX-A-ir in orexinergic neuron output to the ARC 
seen in obese adult mice. In these analyses also the effect of fasting alone 
was monitored (Fig. 31). Whilst no effect was observed in LH OX-A 
neurons, a substantial reduction of OX-A expression was observed in fibers 
of the ARC in leptin-injected ob/ob mice as compared to wt mice (Fig. 31). 
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DISCUSSION AND CONCLUSIONS 
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DISCUSSION 
 
Based on the previously described role of leptin in food deprivation-induced 
“rewiring” of the hypothalamus, and the LH in particular (12), and on the 
important neuromodulatory roles of the endocannabinoid system in this area 
(191, 192), we investigated if remodeling of orexinergic neuronal wiring 
also occurs during a prolonged nutritional perturbation caused by, or 
resulting in, leptin signalling deficiency, as in ob/ob and HFD mice, 
respectively, and its impact on endocannabinoid signalling. First, through 
immunofluorescence and ultrastructural studies in the LH of lean mice, we 
found that, as in other brain nuclei, elements of the endocannabinoid system 
are well positioned to facilitate the retrograde action of post-synaptically 
produced 2-AG onto pre-synaptic CB1 receptors (193, 194). Specifically, 
orexinergic neurons express the 2-AG-biosynthesizing enzyme DAGLα in 
somatic and proximal dendritic compartments and receive afferents that 
express both CB1 receptors and the 2-AG-hydrolysing enzyme, MAGL. In 
lean mice these fibers are mostly glutamatergic/excitatory nature. This 
agrees with previous studies showing that DAGLα is mostly distributed in 
somatodendritic spines apposed to excitatory axon terminals (194), and 
indicating that orexinergic neurons mostly receive excitatory inputs (12, 
191). These data provide for the first time the anatomical basis for the 
previously observed CB1-mediated inhibition of excitatory postsynaptic 
currents and for endocannabinoid participation in depolarization-induced 
suppression of excitation (DSE) in these neurons (191). More interestingly, 
we investigated a possible dysregulation of endocannabinoid 
neuromodulatory actions in the LH during obesity. Our next findings, based 
on a variety of experimental approaches, indicate that: 1) inhibitory axon 
terminals on orexinergic neurons become significantly more numerous than 
excitatory ones in adult and weaned, but not pre-weaned, ob/ob mice and 
adult HFD mice as compared to matched controls; 2) also CB1 and MAGL-
expressing terminals onto orexinergic neurons become predominantly 
inhibitory in obese mice; 3) these rearrangements result in: a) higher mIPSC 
and sIPSC frequency, b) stronger presynaptic inhibition of sIPSC by CB1 
agonists, and c) endocannabinoid-mediated DSI (as opposed to DSE of 
control mice), in orexinergic neurons; 4) 2-AG biosynthesis is elevated in 
the LH of adult ob/ob and HFD mice, thus potentially allowing for stronger 
endocannabinoid-mediated disinhibition of orexinergic neurons in these 
mice. These findings provide unprecedented evidence of a rapid and 
substantial functional rearrangement of endocannabinoid-mediated 
neuromodulation in the brain during obesity. In ob/ob mice, the shift from 
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excitatory to inhibitory transmission in LH orexinergic neurons occurs after 
weaning, i.e. when ob/ob pups stop receiving leptin from the milk of their 
heterozygote dams and become progressively leptin-depleted. This leads to 
the hypothesis that this rearrangement is directly due to lack of leptin, as 
previously suggested for the ARC (6, 7). Neuroanatomical studies have 
suggested that the majority of leptin’s anti-obesity effects are mediated by 
LepRb in the ARC of hypothalamus (158-160), in which  leptin regulates 
the activity of two oppositely acting sets of lepRb-exspressing neurons by 
stimulating anorexigenic neurons that express POMC and CART, and 
inhibiting orexigenic neurons that express NPY and AgRP (123, 161, 162). 
Leptin responsive POMC and NPY/AgRP neurons project to the LH and 
some of them make close anatomical contacts with OX neurons (123, 161, 
162). Furthermore, recent papers show that leptin modulates also the axonal 
growth and synaptic plasticity within the hypothalamus (6, 7) and play a 
crucial role in the control of EC levels (2) and inhibitory or excitatory 
phenotype of arcuate projections to OX neurons (12) In particular, leptin 
increases neurite extension in the ARC during mouse perinatal 
development, thus playing an early trophic role within those circuits that 
will be the target of leptin physiological actions in adult life (6). Moreover, 
an OX1R-selective antagonist reduced food intake and ameliorated obesity 
of leptin-deficient ob/ob mice (134), suggesting that leptin deficiency at 
least partly activates the orexin pathway to increase food intake. 
Accordingly, we found that 24 h leptin administration to adult ob/ob mice 
was sufficient to reverse the observed rewiring of CB1-expressing afferents 
to OX neurons, as assessed by both immunohistochemical analyses and 
functional patch-clamp measurements. Furthermore, experiments in mice 
made obese and leptin resistant by prolonged HFD extend our findings to an 
animal model more relevant to human obesity. This provides further support 
for the involvement of leptin in the observed shift in synaptic populations 
and endocannabinoid signaling, and may suggest that the rearranged CB1-
expressing afferents to LH neurons may originate in the ARC, since: 1) 
HFD mice exhibit leptin resistance in this nucleus, but not in other leptin-
responsive hypothalamic and extra-hypothalamic nuclei (195); and 2) 
efferents to LH orexinergic neurons from the ARC were already known to 
undergo leptin-dependent reorganization following food deprivation in lean 
mice (12). However, in mice with HFD-induced obesity it is also possible 
that the alteration of CB1-mediated regulation of LH neuronal activity may 
have been due to the dysrupted nutritional regulation that follows a 
prolonged HFD. Due to their leptin resistance, it is not feasible to reverse 
the synaptic rearrangement observed in these mice by leptin injection, as 
60 
 
was possible for ob/ob mice. However, in HFD-mice we observed changes 
in synaptic function very similar to those of ob/ob mice. The increased 
levels of 2-AG that we found in adult ob/ob and HFD mice are unlikely to 
be due solely to defective leptin signaling (2). This is not only because 
leptin resistance may not have occurred in the LH of HFD mice40, but also 
because we found that increased 2-AG levels were paralleled by increased 
DAGLα expression, whereas leptin is thought to modify the activity of 2-
AG synthesizing enzymes rather than their expression (2, 192, 196). Finally, 
we also found that the number of OX-A-expressing projections to the ARC 
was significantly elevated in ob/ob mice, from weaning onwards, and is also 
increased in adult HFD mice. One interpretation of this finding is that OX-A 
release is increased in the ARC, since increased release of a neuropeptide 
results in chronic upregulation of its trafficking to terminals. Accordingly, 
expression of pre-proorexin mRNA in the LH was increased with a later 
onset as compared to OX-A release into the ARC, whereas OX-A-ir in the 
LH did not change, possibly as a result of increased production in this area 
and increased release in output regions. These data suggest that the 
potentially enhanced endocannabinoid-mediated disinhibition of orexinergic 
neurons, described here, increases release of OX-A in the ARC, in which we 
found in both ob/ob and HFD obese mice, enhanced expression of OX-A. 
This plasticity could have obvious consequences on increasing appetite and 
body weight, thus possibly resulting in a vicious cycle in which the 
endocannabinoid 2-AG acts as both a trigger and enhancer of food intake. 
This possibility is also supported by the anorectic, thermogenic and anti-
obesity activity of SB-334867-A, a selective orexin-A receptor antagonist, 
in ob/ob mice (9).  
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CONCLUSIONS 
 
In conclusion, we provide here a unique example of how endocannabinoid 
neuromodulatory control over excitatory and inhibitory neurotransmission 
in the brain is profoundly altered as a consequence of leptin-dependent 
rewiring of glutamatergic and GABAergic synapses. In the LH this 
alteration may result in the disinhibition of orexinergic neurons via 
enhanced retrograde inhibition of their inhibitory vs. excitatory inputs. This 
data support our hypothesis that endocannabinoid signaling could really 
exert a powerful modulation of OX-A neurons in the LHA, playing a 
strategic role in feeding control. In particular, during feeding glutamate-
induced hyperactivation of endocannabinoid synthesis may trigger a DSI via 
CB1 receptors which localize prevalently with GABAergic inputs, thus 
inducing disinhibition of OX1 release. A dishinibition of OX-A release 
could occur in the ARC of ob/ob mice as effect of 2-AG-mediated DSI on 
inhibitory inputs to orexinergic neurons thus increasing food-intake. The 
prolonged hypocretin disinhibition subsequent to overexpression of 2-AG as 
an effect of the altered rhythm of feeding may, in turn, trigger a vicious 
circle for feeding itself. Therefore, we have found a drastic rearrangement of 
the EC system, in all its elements, at the level of LH OX neurons during 
obesity, which seems to be explained at least in part by defective leptin 
signaling. In particular, the activity of OX neurons could be modulated by a 
CB1-receptor-mediated inhibitory effect on the GABA inhibitory and/or 
Glutammate excitatory projections (by means of DSI and DSE) controlling 
the activity of the LH OX neurons and the leptin-deficiency modifies the 
distribution of CB1 receptors between excitatory and inhibitory terminals 
leading to a switch from excitatory to inhibitory projections, which would 
alter endocannabinoid-control of neuronal activity. 
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Fig. 11: Peroxidase-based DAGLα and MAGL immunostaining showing 
DAGLα expression in the neuropil and perisomatic punctate structures and 
MAGL expression in punctate structures. Scale bars represent 100 µm.  
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Fig. 12: Expression of the endocannabinoid system at the level of OX-A 
neurons. (a) Distribution of DAGLα in OX-A neurons of the lateral 
hypothalamus perifornical area of adult wt mice. Perisomatic clustering of 
DAGLα in OX-A neurons (arrowheads) and in the neuropil. (b) CB1/MAGL 
co-localization in the neuropil of LH and on many OX-A neurons at the 
perisomatic level as it appears in the asterisk labeled neurons.Scale bars 
represent 60µm (b, c), and 25µm (insert c) 
c 
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Fig. 13: Sequential silver-enhanced double OX/DAGLα or CB1/DAGLα or 
OX/CB1 immunogold electron microscopy in the lateral hypothalamus of wt 
and ob/ob mice 9 week-old. Note that the first primary antibody of each 
adopted mixture generated a larger size than the second primary antibody 
because the corresponding ultra small gold antibody conjugate was 
enhanced twice whereas the second ultra small gold antibody conjugate was 
enhanced only once. (a, b) Intense accumulation of OX in dense vesicles 
(arrows) within the perikaryon (Pe) of cell expressing DAGLα concentrated 
on the somatic membrane (arrowheads) and forming an asymmetrical 
synapse with a putative excitatory terminal (At) (arrowheads). (c) 
Asymmetric, putative excitatory axo-somatic synapse and (d) symmetric, 
putative inhibitory axo-somatic synapse between an axonal terminal (At) 
expressing intense CB1 accumulations (arrows) at presynaptic membrane 
opposite to DAGLα accumulations (arrowheads) at the edges of 
postsynaptic density. (e, f) Intense accumulation of OX immunogold in 
highly dense vesicles (arrows) in the perikaryon of neurons which receive 
an asymmetric putative excitatory CB1-expressing synapse (arrowheads in 
e) or a symmetric putative inhibitory CB1-expressing synapse (arrowheads 
in f). CB1 labeling was detected intensely on edges of presynaptic 
membrane specializations. No differences in the ultrastructural expression 
and localization of each marker were found between the lateral 
hypothalamus of wt and ob/ob mice. Sp, dendritic spine; At, axonal 
terminal; Pe,  perikaryon; Nu, nucleus. Scale bar represents 0.6 µm (a,b), 
0.5µm  (c), 0.4µm  (d,f), 0.3µm  (e).   
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Fig. 15: Double CB1/DAGLα or OX-A/DAGLα pre-embedding 6nm and 10 
nm immunogold electron microscopy in wt and ob/ob mice. (a) Asymmetric, 
putative excitatory axo-dendritic synapses in the lateral hypothalamus of wt 
mice. 6nm DAGLα gold particles are selectively observed at a postsynaptic 
somatic perimembrane specialization of a dendritic spine (Sp, arrowheads). 
10 nm CB1 particles are located in two different axonal terminals (At1 and 
At2, arrows) at the edges of each presynaptic site, opposite to DAGLα. (b) 
Symmetric, putative inhibitory axo-dendritic synapse in the lateral 
hypothalamus of ob/ob mice showing 6nm DAGLα and 10 nm CB1 particles 
distributed as in (a).  (c) 6nm DAGLα gold particles are strictly located 
near the somatic perimembrane compartment  including a postsynaptic side 
(white boxed) of a wt OX-A neuron with 10 nm OX-A gold particles piled in 
heavy dots within dense cytosolic vescicles (black boxed area). (d) High 
magnification of the black boxed area in “c” showing clusters of OX-A gold 
particles. (e) High magnification of white boxed area in “c” showing 6 nm 
DAGLα gold particles (arrowheads) near the internal surface of 
presynaptic plasma membrane. At, axonal terminal; Nu, nucleus; Pe,  
perikaryon, Sp, dendritic spine. Scale bars represent 0.1µm (a,b), 1.4µm (c), 
0.2µm (d), 0.12µm (e). 
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Fig. 15: (a) Histogram showing the density of DAGLα gold particles in 
somata, proximal dendrites and dendritic spines of OX neurons. The 
distribution of DAGLα silver-enhanced immunogold labeling was 
normalized to µm of membrane length of orexinergic neurons by counting 
the number of particles on 5 neurons per animal followed through 24 
consecutive lateral hypothalamus serial ultrathin sections (n=3 mice per 
group). (b) Histogram showing two distinct particle size distributions of 
gold particles silver enhanced, respectively, once vs twice. The mean 
diameter of n=250 particles was of 45.8 +8.50 nm when single enhanced; 
92.5 +12.6 nm when double enhanced. (c,d) Controls of gold particle size 
growing performed by once (c) vs twice (d) silver enhancement of  the 
secondary antibody against CB1 marker. Enhancing  one of the gold labels 
once vs twice resulted in a doubling of size. (e) Negative controls obtained 
by omitting the mixture of primary antibodies. Note the absence of 
immunogold silver enhanced signal . Similar results were obtained by 
omission of the mixture of secondary ultra small antibodies (data not 
shown). Sp, dendritic spine; At, axonal terminal; Pe,  perikaryon. Scale bar 
represents 0.7µm (c,d). 
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Fig. 16: The levels of DAGLα protein expression and 2-AG in the lateral 
hypothalamus increase during obesity. (a,b) 2-AG levels were evaluated by 
LC-MS on the lateral hypothalamus isolated from the brain of mice at 
different ages, genotypes and diets. (c,d) Quantitative analysis of DAGLα 
peroxidase-based immunostaining (optical density or O.D.) performed on 
orexinergic neurons identified on adjacent DAGLα/OX-A immunoreactive 
sections. Means ± s.e.m.; n=500 OX-A neurons per group of ages, 
genotypes and diets; * P < 0.05; ** P < 0.01. 
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Fig. 17: (a) Quantification of pre-proorexin  mRNA expression in the lateral 
hypothalamus of 3, 5 and 9 weeks old ob/ob and wt mice, normalized to the 
reference gene Hprt; n=8 LH in each group; n= 4 animals per group; *** 
P < 0.001 for each comparison. (b-e) Histograms of quantitative 
densitometry scanning  of optical density (O.D.) of peroxidase-based OX-A 
immunostaining during obesity compared to lean mice at each age both for 
genotype and diet. (b,c) Lateral hypothalamic orexinergic neurons showing 
no change in the intensity of OX-A expression; (d,e) fibers of the arcuate 
nucleus (ARC) showing the increase of expression in obese mice after 
weaning. Means ± s.e.m.; n>120 sections per area; n= 3 mice at each age 
for genotype and diet; *P < 0.05 for the comparison of post-weaning and 
adult ob/ob mice vs. the corresponding wt mice or of HFD vs. SFD mice. 
a 
b c 
d e 
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Fig. 18: Abundance of glutamatergic CB1- or GABAergic CB1-expressing 
fibers onto OX-A-ir neurons of the lateral hypothalamus of adult (9 ws) wt 
(a,c) vs. ob/ob (b,d) mice, respectively. 
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Fig. 19: (a, b) Quantitative analysis of the optical density (O.D.) of CB1 
peroxidase-based immunostaining of orexinergic neurons as identified on 
adjacent CB1/OX-A immunolabeled sections of the lateral hypothalamus. 
Means ± s.e.m.; n=500 OX-A neurons per group of ages, genotypes and 
diets. (c,d) Percentage of CB1-expressing fibers projecting to OX-A 
neurons, counted on the total of OX-A synaptophisin-labeled afferences. No 
statistically significant difference was found for mouse genotype, diet and 
age. n= 300 OX-A neurons per group. Means± s.e.m.  
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Fig. 20: Quantitative analysis of CB1/VGAT- vs. CB1/VGluT2-
immunolabeled axon terminals in apposition to OX-A perikarya in the 
lateral hypothalamus. n= 60 OX-A neurons per group, acquired from 
CB1/VGAT/OX-A or CB1/VGluT2/OX-A sections. In the lateral 
hypothalamus of post-weaning (5 ws) and adult (9 ws)  ob/ob or HFD mice, 
CB1/VGAT inputs outnumbered CB1/VGluT2 imputs, contrary to what 
observed in lean mice. No difference was found in pre-weaning (3 ws) wt vs. 
ob/ob mice. Means± s.e.m.; ** P < 0.01 for the comparison of post-weaning 
and adult ob/ob mice vs. the corresponding wt mice or of HFD vs. SFD 
mice. 
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Fig. 21: Triple VGluT2/MAGL/OX-A in  wt and VGAT/MAGL/OX-A in 
ob/ob immunofluorescence showing the abundance of MAGL localization in 
glutamatergic vs. GABAergic fibers perisomatic to OX-A neurons in wt and 
ob/ob mice, respectively. Scale bars represent 50 µm. 
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Fig. 22: Quantitative analysis of perisomatic CB1-expressing boutons (a-d) 
and somato-proximal peridendritic CB1-expressing boutons (e-h) on OX-A 
cells in the lateral hypothalamus. The data were collected from 3 ws (pre-
weaning), 5 ws (post-weaning) and 9 ws (adult) ob/ob and wt mice and from 
16 ws HFD and SFD mice. Only CB1-expressing boutons with clearly 
identified symmetric or asymmetric morphology were selected for analysis. 
In post-weaning and adult ob/ob mice and in adult HFD mice, CB1 
symmetric synapses outnumbered CB1 asymmetric contacts both in 
perisomatic and dendritic compartments. No difference was found in pre-
weaning wt vs. ob/ob mice both in perisomatic and dendritic compartments. 
Means± s.e.m; * P< 0.05; ** P < 0.001. 
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Fig. 23: Percentage of asymmetric and symmetric CB1-expressing boutons 
per µm of OX-A membrane of adult (9 weeks old) lean and  ob/ob mice. 
Asymmetric CB1-expressing boutons outnumbered symmetric ones per µm 
of OX-A membrane of wt and SFD adult mice. An opposite scenario was 
found in adult obese ob/ob and HFD mice. The value are expressed as mean 
percentage ± s.e.m ; ** P < 0.01, *** P < 0.001  for the comparison of 
adult ob/ob mice vs. the corresponding wt mice or of HFD vs. SFD mice. 
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Fig. 24: Orexinergic neurons of ob/ob mice become more inhibited then wt 
after weaning. Mean ± s.e.m. frequency of mIPSCs in ob/ob and wt orexinergic 
neurons before and after weaning. * P < 0.05, ** P < 0.005. 
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Fig. 25: Absolute values of sIPSCs frequency and amplitude in ob/ob and wt 
orexinergic neurons in control condition and in the presence of WIN (5 µM, n = 
9 in both groups). The inhibitory synapses acting on ob/ob orexinergic neurons 
are strongly depressed by the CB1 agonist WIN55,212-22 (WIN). Data are 
expressed as mean ± s.e.m. ** P < 0.01. 
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Fig. 26: (a) Relative frequency of sIPSCs in the presence of: WIN (5 µM, n = 9 
in both groups) or the CB1-receptor antagonist AM251 (AM, 4 µM, n = 6 and 
5, ob/ob and wt respectively), and AM with 5 µM WIN (AM+WIN, n = 6 and 4, 
ob/ob and wt respectively). The dashed line marks the reference sIPSC 
frequency in control conditions. (b) Relative amplitude of sIPSCs in the 
presence of: WIN, AM251 and AM+WIN. Same neurons as in (a). The dashed 
line marks the reference amplitude in control condition. Data are expressed as 
mean ± s.e.m. * P < 0.05, *** P < 0.001. 
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Fig. 27: Mean ± s.e.m. frequency of sIPSCs as a function of time (5 s bin) after 
a 5 s step-depolarization to 0 mV (“stim.” and the corresponding thicker 
portion of the abscissa), relative to the frequency 5 s before the depolarization 
in ob/ob orexinergic neurons before (contr.) and after (AM) the addition of AM. 
n = 11 in both groups. *** P < 0.001. 
a 
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Fig. 28: Effect of intraperitoneal leptin administration on the rewiring of 
OX-A neurons in the lateral hypothalamus of ob/ob mice. Triple 
CB1/VGAT/OX-A and CB1/VGluT2/OX-A immunofluorescence showing the 
scarcity of CB1 expression in inhibitory fibers and the abundance of CB1 
expression in excitatory fibers, respectively, onto OX-A neurons in the 
lateral hypothalamus at the perisomatic level in adult ob/ob mice. Scale 
bars represent 50 µm. 
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Fig. 29: Quantitative analysis of CB1/VGAT- vs. CB1/VGluT2-
immunolabeled axon terminals apposed to OX-A perikarya, performed after 
leptin injection plus fasting in adult ob/ob mice. Leptin administration 
reverses the synaptological alteration of OX-A neurons in the lateral 
hypothalamus of obese mice. Means± s.e.m; ** P < 0.001 for the 
comparison of CB1/VGAT-  vs. CB1/VGluT2-immunolabeled axon terminals 
in leptin-injected adult  ob/ob mice. Lines denote the amount of CB1/VGAT- 
vs. CB1/VGluT2-immunolabeled axon terminals in adult untreated wt ad 
ob/ob mice fed ad libitum. 
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Fig. 30: Leptin equalizes the number of functional inhibitory synapses of ob/ob 
orexinergic neurons to wt levels. Mean  ±  s.e.m.  mIPSC frequency in neurons 
from 5 weeks old mice with 24h fasting + leptin administration. Dashed and 
solid lines are the mean frequency levels of, respectively, ob/ob and wt mice fed 
ad libitum. * P < 0.05, ** P < 0.01. 
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Fig. 31: The amounts of OX-A in the ARC is increased in adult ob/ob mice in a 
manner reversed by leptin injection. The intensity of the OX-A signal (O.D.) in 
the lateral hypothalamus (LH) is not different between wt and ob/ob mice, 
whereas its intensity is enhanced in the ARC of adult ob/ob mice and reduced 
in ob/ob but not wt mice 24h after leptin administration plus fasting. Dashed 
and solid lines represent the mean OX-A optical density in untreated wt ad 
ob/ob mice fed ad libitum, respectively. Means ± s.e.m.; n=3 mice per group. 
*P < 0.05; **P < 0.01. The images show an high peroxidase-based OX-A 
immunoreactivity in neurons of the lateral hypothalamus and an higher 
peroxidase-based OX-A immunoreactivity in fibers projecting to the ARC in 
HFD and ob/ob mice compared to SFD and wt, respectively. This alteration is 
reversed by intra peritoneal treatment of leptin and fasting for 24 h, which 
instead did not affect wt mice. Scale bars  represent 150 µm (LH) and 20 µm 
(ARC). 
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